cryopreserved at -80C. There were 52 males and 38 females. The median age was 40 years (range 14 to 68). The median interval between the diagnosis and the transplant was 9 (2.3-84.4) months. The median number of leukapheresis was 3 (1-7). The median count of mononuclear and CD34+ cells reinfused after the preparative regimen (multiple myeloma: 200mg/m2 melphalan; acute leukemias: busulphan/cyclophosphamide; lymphomas: BEAM or busulphan/VP-16/ cyclophosphamide) were 7.7 (2.2-21.9)x108/kg and 11.4 (1.1-132.4)x106/kg, respectively. All but one pts received more than 2.5x106/kg. CD34+ cells. Growth factor was administered all pts until neutrophil engraftment. Neutrophil and platelet engraftments occurred on days 10 (range 7 to 9) and 13 (range 0 to 104), respectively.Although CD34+ cell counts (>10x106/kg), time interval more than 1 year between diagnosis and transplantation and BEAM conditioning found significant in univariate analyses none of them found to be meaningful in multivariate analysis for neutrophil engraftment, In univariate analysis graft CD34+ cell counts (>7x106/kg) and the primary diagnosis of multiple myeloma were found to be significant predictors of platelet recovery. But only CD34+ cell count remained significant after multivariate analysis (p<0.05). In conclusion, the CD34+ cell counts effect the platelet recovery in APBSCT.
Transplantation of haematopoietic stem cells from blood or bone marrow (HSCT) has seen a rapid expansion. In developing countries, where incomes are low, any reasonable effort in order to reduce expenses of the HSCT is welcome. We want to identify the cost of a HSCT in an eastern-Europe developing country, Romania, with 22 million inhabitants, where the gross national product per capita was 1500 Euro in 2001, where we have only public health care system and 3 transplant teams which performed in the last eighteen months 12 transplants. To find out the cost of a transplant, we performed a retrospective study in a single institution between June 2001 (the date of the first transplant in our country) and October 2002. Our clinic performed five autologous peripheral blood stem cell transplantations, out of which 4 were performed in children (3 Hodgkin`s disease (HD) and a neuroblastoma) and one in an adult with HD. We collected the data from the remission reinduction chemotherapy cycles (followed by cytapheresis), the pretransplant investigations, the transplant, the intensive care in the period of the hospitalization and one year follow up. We did not include the staff pay, the structure costs and the stay in the hospital. The mean cost of a transplant was 24650 Euro per patient with the follow distribution: 56,3% for drugs; 15,2% for transfusions; 5,4% for harvesting; 7,4% for materials; 8,7 for exploring maneuvers and blood tests and 6,7% for other costs. These data provide a basis for health care planning concerning the cancer treatments in our country and future directions to decrease costs (which are high because of our lack of experience): administrations of high dose CD34+ cells, reduction of hospitalization period, delay administrations of G-CSF after transplant or even G-CSF withdrawal in children (in prospective studies).
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Influence of G-CSF dose and mobilization timing on the maturation stage of peripherally harvested hemopoietic progenitor cells in children with solid tumors L.G. Mathew, S.R. Patel, N. Pandya, P. Connor, S. Vaidya, D. Rajapakse, C.R. Pinkerton, J. Treleaven, M. Ortin (Sutton, UK) Introduction: Previous studies have suggested that doses of Granulocyte-Colony Stimulating Factor (G-CSF) higher than 5 micrograms/Kg could possibly mobilise different subsets of haemopoietic progenitor cells (HPC) in patients having peripheral blood HPC harvests. With the aim of searching for differences in the HPC subsets mobilised by different dosages of G-CSF, we retrospectively analysed all the mobilisation-harvest procedures performed at our Department in the last 5 years. Patients and methods: From 1997, 55 children received autologous peripheral blood HPC transplants as consolidation treatment for solid tumours. Data on the mobilisation/harvest procedure were available in 51 cases (31 boys, 20 girls, median age 6±4.4 years). G-CSF was administered for 4 consecutive days at doses of 5 (35 cases) or 10 micrograms/Kg/day (16 cases). A first harvest was performed on the 5th day. A second session was performed on the 6th day in 45/51 cases. Harvests were performed 28.3±23.9 days after the last course of chemotherapy. Yields of CD34+ and CD34+CD33-cells were measured. Results: No significant differences were found between the overall number of CD34+ cells yielded by one or other mobilisation regime (8.6±14.9 vs. 4.2±3.5 x106 CD34+ cells/Kg). However, the percentage of CD34+CD33-cells was significantly higher (p<0.05) in patients mobilised with 10 micrograms/Kg of G-CSF. These differences were also significant when first and second sessions were separately compared (p<0.03 and p<0.02). Harvests performed within the first 14 days after the last course of chemotherapy contained a significantly higher (p<0.04) proportion of early CD34+CD33-progenitors, although the overall number of CD34+ cells harvested was not significantly different. Conclusion: Our results confirm that higher doses of G -CSF mobilise "earlier" (more immature) HPC. This could possibly result from stimulation of earlier progenitors that present a lower density of receptors for G-CSF on their surface. The differences observed might contribute to the lower immune reactivity (veto effect) observed in allogeneic grafts of megadoses of CD34+ cells, where HPC are mobilised with high doses of G-CSF. We also observed a higher proportion of early HPC when children were harvested within the first 2 weeks after the last course of chemotherapy. Prospective studies should be directed towards complete characterisation of the different subsets of HPC yielded by different doses of G-CSF.
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A retrospective study on the influence of CD34+CD33-''early'' progenitor cells in the outcome of autologous grafts in children with solid tumors S.R. Patel, L.G. Mathew, N. Pandya, P. Connor, D. Murphy, S. Vaidya, C. Duncan, C.R. Pinkerton, J. Treleaven, M. Ortin (Sutton, UK) Little is known about the influence of early (CD34+CD33-) haemopoietic progenitor cells (HPC) on haemopoietic reconstitution or complications after autologous peripheral blood progenitor cell transplants (APBPCT). The aim of this study is to assess if this cellular subset has any impact on the outcome of children receiving APBPCT as treatment for solid tumours. From 1997, 55 children (32 males, 23 females, median age 6±4.2 years) with solid tumours were treated with APBPCT. The conditioning regimens included melphalan (26 cases); busulphan plus melphalan (10); thiotepa plus etoposide (2); cyclophosphamide plus melphalan (7); cyclophosphamide, carboplatin plus etoposide (4); carboplatin (2); carboplatin plus melphalan (1) and carboplatin plus etoposide (3). The average number of CD34+ cells administered was 7.05±12.17x106 CD34+ cells/Kg, with an average 3.04±3.06 x106 CD34+CD33-cells/Kg. G-CSF was given in all cases from day +8 until the neutrophil count reached 4x109/L. To assess the influence of early HPC on outcome, we analysed the incidence of various post-transplant events, namely derangement of renal or liver function, days of pyrexia, time to platelet and neutrophil recovery, engraftment syndrome and need for transfusions, in relation to the percentage of CD34+CD33-cells administered. There was no difference in liver, renal function derangement, number of days of pyrexia or incidence of engraftment syndrome. Days to neutrophil (>0.5 neutrophils x109/L) or platelet (>20 platelets x109/L) recovery were not significantly different, although these results might be confounded by the administration of G -CSF. We then studied time to platelet recovery to 50 x109/L, when no influence from G-CSF should be expected. We found that patients receiving grafts containing more than 50% CD33-cells within the CD34+ subset recovered 50 platelets x109/L significantly (p<0.05) sooner than children receiving grafts with lower percentages of CD33-cells. In addition, a non-significant trend to use less blood products was found in this group of patients. Our results suggest that the number of CD34+CD33-cells (an earlier HPC subset within the CD34+ population) influences longterm haemopoietic reconstitution after APBPCT in children treated for solid tumours. Prospective studies should be directed at assessing other possible effects of infusing early progenitors on patients receiving autologous and allogeneic grafts.
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Treatment of primary hemophagocytic lymphohistiocytosis with allogeneic stem cell transplantation from donors other than matched siblings A. Munoz, A. Martinez, C. Diaz de Heredia, I. Badell, M 
.S. Maldonado on behalf of the Spanish Working Party for BMT in Children (GETMON)
Primary Hemophagocytic Lymphohistiocytosis (HLH) is a rare and fatal autosomal recessive immunoregulatory disorder for which the only curative treatment is allogeneic Stem Cell Transplantation (SCT). We report our experience with this procedure in 7 patients with primary HLH with no matched sibling donors. Age of children at onset of disease ranged from 2 months to 108 months (median 2.5m). There were 4 males and 2 females and all patients presented with fever, hepatoesplenomegaly, pancytopenia and bone marrow infiltration. In 5/7 cases there was CNS infiltration at diagnosis and in 4 NK cells activity was impaired. All patients were initially treated with HLH-99 Protocol: dexametasone, VP-16, Cyclosporine (CSA) and intrathecal methotrexate(MTX) Median interval from diagnosis to SCT was 10 months(5m to 18m). At transplant 5/7 patients showed active disease (including SNC infiltration in 3), while 2 patients were in remission. Five patients received a graft from an HLA identical unrelated donor (URD), 1 patient was transplanted from an unrelated cord blood with 2ag mismatched and 1 patient was transplanted from an haploidentical related donor. GVHD prophylaxis was performed with CSA and MTX in URD and cord blood transplants and with CSA and T-cell depletion in the haploidentical tranplant. ALL patient underwent the same conditioning regimen: ATG, Busulfan, cyclophosphamide and VP-16. Two of the 5 patients transplanted from an URD are alive and disease-free 52 months and 37 months after SCT. The remaining patients died, 2 from disease progression and 3 from transplantrelated causes (2 acute GVHD an 1 chronic GVHD) Conclusions: Our results corroborate that SCT from and URD is a valid treatment option for primary HLH patients and underscores the need to: 1) shorten the search time for donors in order to prevent disease progression and 2)improve the prophylaxis and treatment of GVHD.
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Successful hemopoietic stem cell transplants using nonradiotherapy based conditioning regimens in patients with Fanconi's anemia J. Motwani, S.E. Lawson, P.J. Darbyshire (Birmingham, UK) We present a single-centre experience of using alternative donors and a low toxicity, non-radiotherapy containing conditioning regimen with low rejection rates in a series of patients with Fanconi's anemia (FA) undergoing hemopoietic stem cell transplants (HSCT). 6 children with FA (4 females, 2 males), who had not undergone transformation and were not dependent on blood products, received 8 HSCT between 2000-02. All received similar conditioning regimen: Fludarabine 25-30mg/sqm/d for 5 days, Antilymphocyte globulin 12.5mg/Kg/d for 3 days and Cyclophosphamide 5-7.5mg/kg/d for 4 days. Radiation was not used for any patient. 1 male patient who had multiple HSCT and 1 female who was retransplanted, received a slightly different conditioning regimen. 3 patients had fully matched unrelated umbilical cord blood, 2 had matched unrelated donor graft, and 3 had haploidentical PBSC grafts, which were TCell depleted (TCD) before re-infusion. None of our patients had any conditioning related toxicity. All engrafted within 2-3 weeks post-HSCT. 1 patient rejected her first HSCT (TCD haploidentical graft) after 10 weeks. She had a second successful transplant from the same donor. The male patient had a TCD haploidentical HSCT from his mother, which engrafted but rejected after 1 week. He subsequently had a successful fully matched unrelated umbilical cord blood transplant. Our observed rejection rate is 25%. All patients are fully donor chimaeric and well after a median follow up of 6 months (range 3-33 months). 6 of 8 (75%) had grade 2-3 graft versus host disease ( GVHD) involving skin, gut, liver or a combination. Steroids were used to treat GVHD in all patients, and in 2 patients immunosuppressive therapy was changed from cyclosporin to tacrolimus. Incidentally, those patients who rejected were ones who did not have any GVHD. All patients had one or more episodes of febrile neutropenia, but none had any severe fungal, CMV or other viral infection. 5 of 6 evaluable patients have had good immune recovery (for 1 patient it is too early for assessment). Conclusion: The use of a conditioning regimen without radiotherapy is possible in FA even when using alternative donors. This regime was associated with low toxicity and a predictable rejection risk when T cell depletion used. Alternative donors should be considered early in FA before transformation or significant exposure to blood products, both of which are likely to increase transplant related mortality.
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Unrelated BMT in thalassemia: use of single donor for monozygotic twins B. Erer, M. Donati, C. Giardini, O. Buffi, A. Iliescu, S. Stramigioli, S. Nesci, P. Polchi, G. Lucarelli (Pesaro, I) Two four year old Sicilian female monozygotic twins with beta thalassemia major, were submitted to BMT from a MUD in Pesaro BMT Center. A search for a MUD for both patients was started on September 2000 in our Center. On march 2001 an Italian (Sicilian) matched donor was identified. The patients and the donor were completely identical for two extended HLA haplotypes (Table 1) . As the standards of IBMDR accept "one donor -one recipient", we asked a consensus to GITMO to proceed to transplant for both patients using the same donor. We considered the body weight of each patient (12 kg) and of the donor (58 kg), and therefore the possibility to give sufficient marrow cells to both patients using the same donor with single marrow harvesting. The consensus was given and the twins were submitted to BMT on May 2002 after a conditioning regimen with BU14 + TT 10 + CY 200 (CsA+sMtx for GVHD prophylaxis). The dose of nucleated cell infused was 4,2 x 108 / kg for each patient after separation of RBCs (Table 2 ). The allogeneic engraftment was documented on day +20 (full donor chimera on bone marrow). The post-BMT period was uneventful exept for the reactivation of CMV for which each patient received pre-emptive therapy. They went back home +4 months after transplant in good clinical conditions. At the last control of +6 months after transplant, both patients showed full donor chimera on bone marrow withouth GVHD, and they were in optimal clinical conditions. The BMT for thalassemia from MUD identical by extended haplotypes offers similar results to those obtained with HLA identical familiar donors. We report the first case of concomitant use of a single donor for two patients.
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Successful bone marrow transplantation in 9-month-old patient with chronic granulomatous disease S. Kansoy, S. Aksoylar, N. Kutukculer, M. Kantar, K. Kavakli, N. Cetingul (Izmir, TR) Chronic granulomatous disease (CGD) is a rare inherited immunodeficiency disorder characterized by recurrent, often lifethreatening bacterial and fungal infections and granulomas in multiple organs. Bone marrow transplantation (BMT) in CGD can be curative and has been successful in several patients . Cure of the disease can be achieved by stem cell transplantation when performed early in its course and before severe infections have developed. To our knowledge, among at least 25 CGD patients who underwent BMT, only two of them younger than 12 months of age. A 7-month-old Turkish boy was diagnosed with CGD when he presented with recurrent severe pulmonary infection. Oxidative burst activity with flow cytometric test was 6%. BMT was performed when he was 9-month-old from his healty 3.5 -yearold HLA-matched sister after conditioning with busulphan and cyclophosphamide. A total of 3.9x108 /kg nucleated cells were infused on day 0. No serious complications or GVHD was observed. Sustained engraftment has occurred, as indicated by return of the oxidative burst activity (OBA) to normal on 24 months posttransplantation. OBA as assessed on flow cytometry were 61%, 71% and 85% at 2, 5 and 24 months post transplant, respectively. He was infection free with normal growth parameters at 27 months posttransplant. The successful outcome in this patient demonstrates that BMT should be considered for CGD treatment before septic foci and irreversible organ damage have occurred when an HLAcompatible sibling is available.
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Bloodstream infections and invasive mycoses after hematopoietic stem cell transplantation in children E. Castagnola, G. Dini, S. Dallorso, M. Faraci, G. Morreale, B. Cappelli, R. Haupt, A. Pistorio, M. Barretta, G. Losurdo, I. Caviglia, E. Lanino (Genoa, I) We evaluated the etiology of bloodstream infections and invasive mycoses following 630 hematopoietic stem cell transplantations (HSCT) procedures performed from 1984 to 2000 at G. Gaslini Children's Research Institute, Genoa -Italy, with a total of 14845 months. Among the 213 infectious episodes documented after 168 HSCT, 187 (87%) were bloodstream infections (123 Gram-pos., 51 Gram-neg, 12 Mixed) and 27 (13%) mycoses (1 isolated fungemia, 15 invasive documented and 11 invasive probable or possible); 142 episodes (67%) were diagnosed in presence of neutropenia and 50 (23%) were correlated with the presence of a central venous catheter. The percentage of procedures complicated by at least 1 infectious episode was significantly higher (55%) in this group of children when compared to recipients of match-related (13%) or autologous (BM: 31%; PBSC:12%) HSCT (p < .001). Infectious episodes were mainly due to Gram-posivives, while invasive mycoses were less frequent and mainly observed in children receiving HSCT from a matched unrelated donor or a mismatched HSCT. Patients receiving a HSCT from a matched unrelated donor or a mismatched HSCT had a higher incidence of infections, both bloodstream or invasive mycoses.
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Succesfull cidofovir treatment of late-onset hemorrhagic cystitis in children after allogeneic hematopoietic cell transplantation E. Gorczynska, K. Rybka, D. Turkiewicz, A. Dyla, Z. Szczyra, J. Toporski, K. Kalwak, B. Jankowski, A. Chybicka (Wroclaw, PL) The aim of the study was to compare clinical course of hemorrhagic cystitis (HC) in two groups of children -treated with cidofovir (VISTIDE, Pharmacia Upjohn) or receiving conventional symptomatic treatment only. Material: Between November 2000 and November 2002 HC was diagnosed in 20 out of 87 children (28%) who underwent allogeneic hematopoietic cell transplantation (alloHCT) with myeloablative, busulfan-based conditioning. Methods: HC was diagnosed basing on clinical symptomes, urine analysis and ultrasound imaging of the bladder. All children were treated with hyperhydratation and conjugated estrogens. Cidofovir was given in a dose of 5mg/kg, 2 first doses weekly, then every 2 weeks. HC was classified as mild if no invasive treatment was necessary, moderate if bladder catheterization with or without irrigation was used and severe if children required cystoscopic removal of the blood clots from the bladder. Children transplanted after March 2002 were screened for ADV and BKV DNA in both peripheral blood and urine with PCR-based assay Results: All 9 screened children had BKV (8) or ADV(1) DNA detected in urine. Remaining 12 patients had no viral PCR performed, however late onset of HC (median time from BMT to HC was 32 days) suggested viral etiology. Nine out of 20 children were treated with cidofovir. Five children received 2 doses of cidofovir, 3 children 3 doses, 1 child 1 dose and 1 child 4 doses. No toxicity including renal impairment related to cidofovir treatment was noted. In 8 out of 9 treated children HC symptomes resolved after 20 to 63 days (median 35 days); in 1 patient mild HC syptomes persisted 41 days until death due to bacterial sepsis. Among 11 children without cidofovir treatment resolution of HC was observed in 7 with median duration of 36 days (range 20 to 50 days). Four children died with active HC lasting 23 to 91 days. In the treated group, HC was classified as mild in 6 and moderate in 3 children. In untreated group, HC was classified as mild in 3, moderate in 1 and severe in 7 patients. Two patients in untreated group with severe HC symptoms required renal replacement therapy due to acute renal failure and finally died without HC resolution. Conclusion: Cidofovir treatment of HC in children after alloHCT was well tolerated. Severity of HC clinical symptoms was markedly reduced in children treated with cidofovir in comparison to historical untreated group. Majority of patients (5) required only short treatment with 2 doses of cidofovir to achieve clinical improvement.
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Chimerism guided immunotherapy in children with acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation E. Gorczynska, D. Turkiewicz, J. Toporski, K. Kalwak, B. Rybka, R. Ryczan, A. Chybicka (Wroclaw, PL) Children with acute lymphoblastic leukemia (ALL) relapsing after allogeneic hematopoietic cell transplantation (alloHCT) may benefit from enhanced GvL effect. However, immunotherapy of frank hematological ALL relapse has limited efficacy. Sequential monitoring of hematopoietic chimerism may identify patients at highest risk of leukemia recurrence and allow initiation of immunotherapy while tumor burden is limited. The aim of our study was to analyze the efficacy of immunotherapy initiated in ALL children with increasing amount of autologous DNA after alloHCT (inMC). Material: Immunotherapy was initiated in 11 children with ALL, 4 males and 7 females with median age of 10 years (range 3-17 years). All children received alloHCT, 6 from HLA identical siblings, 3 from matched unrelated donors and 2 from haploidentical parents. Conditioning was busulfan (10) or treosulfan (1) based, in combination with cyclophosphamide and VP16 (8), cyclophosphamide alone (2) or fludarabine and melphalane (1). GvHD prophylaxis consisted of CsA alone (3), CsA and MTX (6) and T-cell depletion (2). Methods: Chimerism was monitored weekly with semiquantitative fluorescent PCR-STR approach in mononuclear cells collected from peripheral blood (PB). Immunotherapy was initiated after confirmation of inMC status (increasing amount of autologous DNA in 2 separate assessments) if no GvHD was present and after informed consent had been obtained from parents and patients according to institutional guidelines. In children receiving immunosuppression CsA was withdrawn immediately. In 2 children transplanted with T-cell depleted graft DLI with low dose of CD3+ (5x10^4/kg) cells was given as front line treatment. Results: Two children did not respond, one of them progressed to overt hematological relapse, the other rejected the grafted marrow. Nine children responded with conversion to complete donor chimerism (CC), 7 after CsA withdrawal, 1 after low-dose DLI and 1 after DLI with 1x10^7/kg CD3+ cells after unsuccessful cessation of CsA. Five of them remain alive in CR from 5.5 months to 2 years after initiation of immunotherapy. Two patients died in CR, 1 due to aGvHD and 1 due to infection. One child developed isolated CNS relapse despite being CC in both PB and bone marrow. GvHD occurred in 7 children, all children with GvHD responded. Conclusions: Immunotherapy with CsA withdrawal or DLI may lead to conversion to CC in children with ALL and inMC after alloHCT. However, response can be transient and appears to be associated with aGvHD.
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Different B-cell repertoire reconstitution after autologous and allogeneic hematopoietic stem cell transplantation analyzed by IgHCDR3 fingerprinting on 24 children D. Di Martino, M.P. Terranova, A. Valetto, P. Di Michele, F. Scuderi, L. Scarso, P. Petrone, B. Cappelli, G. Dini, M. Miano, G. Morreale, S. Dallorso (Genoa, Pisa, I) Immunological reconstitution is one of the problems arising after autologous and allogeneic hematopoietic stem cell transplantation (HSCT). In fact, the immunoincompetence lasted for up to several months after transplantation is the cause of many infectious complications. Besides, in allogeneic HSCT, acute and chronic graft-versus-host-disease (GVHD) hampers immune reconstitution. Several components of the immune system (T,B and NK cells) are involved in immunological repertoire activation. To better define the mechanisms and kinetics of B-cell repertoire reconstitution after the two different kinds o f transplantation in children, we have performed a molecular and citofluorimetric analysis in recipients of autologous (n=12) and allogeneic HSCT (n=12) at our Institute. The molecular technique used is IgHCDR3 fingerprinting: RNAs are extracted from mononuclear cells by peripheral blood obteined before and at various timepoints after HSCT; after reverse transcriptase polymerase chain reaction (RT-PCR), two consecutive PCR are performed with specific primers (variable regions: VH3, VH4, VH6 and constant region: IgM). PCR products are then separated on polyacrylamide gel and silver stained. B,T and NK cells antigen expression and coexpression are also analysed with a large panel of Monoclonal Antibodies (MoAbs) by fluorescent activated cell sorter (FACS) at the same time-points of molecular analysis. CDR3 is one of the hypervariable segments of IgH chain that directly interacts with antigens. In normal B -cell repertoire IgHCDR3 fingerprinting shows a policlonality, characterized by 16-20 bands (each band corresponds to one length of CDR3), while in patients analyzed after transplantation we observe a strong oligoclonality (2-9 bands detected) for VH3 and VH4 gene family and almost a monoclonality (only one band detected) when VH6 gene family is studied. The recovery of a CDR3 policlonal repertoire (³10 bands) is within 2-3 months after autologous HSCT and within 6-12 months after allogeneic HSCT. The FACS-citofluorimetric analysis shows an evident correlation with molecular data. Our preliminary study suggests t hat allogeneic HSCT appears to induce a slight delay recovery of B -cells in comparison to autologous HSCT. ClonalIy restricted IgHCDR3 size distribution in the emerging repertoire seems to be due to functional and numerical B-cell defects (adult-type features), without an evident correlation with a fetal ontogenesis.
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Increasing mixed chimerism identifies high risk of treatment failure in patients with myeloid malignancies after allogeneic hematopoietic cell transplantation D. Turkieiwcz, E. Gorczynska, J. Toporski, K. Kalwak, B. Rybka, R. Ryczan, A. Chybicka (Wroclaw, PL) The clinical significance of mixed chimerism detection is still a matter of debate. Relationship between the presence of autologous cells after transplantation and outcome of transplant procedure may be influenced by many different factors with type of underlying disease being among the most important ones. Our study tries to evaluate evolution of different chimerism patterns in children with myeloid malignancies after allogeneic hematopoietic cell transplantation (alloHCT). Material: Hematopoietic chimerism was monitored in peripheral blood (PB) collected from 35 children (median age 9.5 years) with myeloid malignancies (AML 15, CML 8, JMML 6, MDS 6) after alloHCT with busulfan -based myeloablative conditioning. Children were transplanted from HLA identical siblings (10), mismatched family donors (13) and matched volunteers (12). Children transplanted from alternative donors received ATG in conditioning; those transplanted with T cell depleted grafts ATG or Campath 1H in combination with OKT3. GvHD prophylaxis consisted of CsA alone (7), CsA+MTX (21) or T cell depletion only (7). Median follow-up reached 6 (1.3-31.5) months. METHODS: Chimerism was monitored with fluorescent semiquantitative PCR-STR assay in MNCs isolated from PB with density gradient centrifugation. PB was collected weekly from engraftment until discharge and later during each medical checkup (monthly or every 2 months). Results: Five different chimerism patterns were o bserved: autologous recovery (AR -presence of exclusively autologous cells), complete donor chimerism (CC -only allogeneic DNA at any time after procedure), increasing (in) or decreasing (de) mixed chimerism (inMC) if number of autologous cells respectively increased or decreased (at least 5% difference) in subsequent assessments. AR occurred in 3 children -two subsequently relapsed and one failed to engraft. InMC was observed in 4 children -3 rejected the graft and 1 relapsed. Among 7 children with deMC 1 relapsed without transient inMC stage, 1 died due to GvHD and 5 remain alive in CR. CC was observed in 22 patients, 1 relapsed, 11 remain alive in remission and 10 died due to transplant-related causes. Conclusions: No long-term survivors were observed among children with AR and inMC. They represent a group of patients with the highest risk of treatment failure. However, CC and deMC not necessarily indicates that a patient is free of disease and relapse can occur without preceding transient inMC stage.
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Semiquantitative monitoring of hematopoietic chimerism does not predict treatment failure in children with aplastic anemia after allogeneic hematopoietic cell transplantation D. Turkiewicz, E. Gorczynska, J. Toporski, K. Kalwak, B. Rybka, R. Ryczan, M. Slociak, A. Chybicka (Wroclaw, PL) Graft rejection still remains among the most important causes of treatment failure in children with aplastic anemia (AA) after allogeneic hematopoietic cell transplantation (alloHCT). In children with malignancies, serial quantitative monitoring of hematopoietic chimerism identifies patients with the highest risk of relapse or graft failure after transplantation. In our study we have asked a question weather chimerism can also predict treatment failure in children with AA. Material: Chimerism was monitored in 7 children, 4 females and 3 males with median age of 8 (1.5 -16.5) years. Two children were diagnosed with Blackfan-Diamond anemia (BDA), 5 with very severe aplastic anemia (vSAA). Five children were transplanted from HLA id siblings, 1 from HLA matched volunteer donor and 1 from mismatched family member. Conditioning included CY +ATG(4), BU+CY+FLU+ATG(1), BU+CY+ATG(1), BU+CY+ATG+OKT3(1), GvHD prophylaxis consisted of CsA+MTX(6) or T-cell depletion + CsA(1). Methods: Chimerism was monitored with PCR-STR assay (5) or FISH analysis of sex chromosomes (2) in MNCs isolated from peripheral blood (PB). PB was collected from patients every 2 weeks from engraftment till discharge, thereafter during each medical check-up. Results: In 2 patients exclusively donor cells were detected at any time after transplantation. One of them is alive and well 784 days after alloHCT, 1 died due to GvHD on day + 200. In 1 child stable low-level mixed chimerism was detected with percentage of autologous cells not exceeding 10%. The child is alive and well 3 years after transplantation. One child experienced autologous recovery with transient remission of underlying disease. In 3 patients mixed chimerism was observed with percentage of autologous cells ranging from 11 to 75 with no clear trend detectable. Two of them are alive and well with no evidence of disease 585 and 171 days after transplantation. One developed secondary graft failure and was successfully transplanted from the same donor. Graft failure was not heralded by any evident change in chimerism and the percentage of autologous cells did not exceed 50% at time of graft failure. Conclusions: Mixed chimerism in children with AA after alloHCT not necessarily heralds incipient treatment failure. Children with high percentage of autologous DNA may function with no evidence of disease. Unlike in children with maliganacies, in aplastic anemia s patients with mixed chimerism percentage of autologous cells may fluctuate with no apparent direction.
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School attendance with new IT-technology after allogenous stem cell transplantation T.T. Salmi, P.M. Lähteenmäki, T.K. Tuomarila, K. Kemppi, H. Mantila (Turku, Masku, FIN) School attendance after stem cell transplantation is always a problem. During the stay in transplantation unit, the Hospital teacher takes care of education. After return to home, normal school attendance is not possible because of the risk of infections. According to the Finnish laws, the home community is forced to organize tutoring by home visits of the teachers. This is an unpractical, expensive and poorly working system. Also the lack of personnel prohibits this kind of activities. Very important issue is also the lack of social contacts with schoolmates. The use of new IT-technology can give good possibilities to avoid these problems. We have now started a pilot study to organize school attendance by using IT-technology. When the patient has recovered so that he/she can stay at home, the local tele-company builds connections between school and the patient's home. At school, a video conference equipment is needed including videocamera, normal TV set and coder. An ISDN-line between school and patient's home is needed as well. At home, the patient has to have a PC, ISDN-card, v ideophone program and camera. Software for the computer is needed. It is very important to find a suitable position for the microphone, camera and TV-screen in the classroom in order to have an immediate contact between all classmates and the patient. In this way it is possible to include the patient in intimate social surrounding of his/her own school-class. The patient belongs to the group of pupils and can attend the education almost as closely as the others. He/She can follow all lessons and be as an active pupil as all the others. The only practical problem has been, that the patient can not sing together with classmates because of the small delay in transmitting the voices. This solution is very effective and economical. All equipment and other fees are about 2000 Euro for a patient during all education. To have private tutoring would be ten times as expensive. The technology used is a routine one and no special equipment is needed. So it is possible to be used in all circumstances, if just a telephone line is available.
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Hemopoietic stem cell transplantation in childhood: improved survival over the years and reduction of transplant-related mortality in the autologous setting A. Marín-Niebla, I. Espigado, R. Parody, J.-M. Pérez-Hurtado, M. Carmona, E. Ríos, J.-M. Rodríguez-Fernández (Sevilla, E) Background: Stem cell transplantation (SCT) is an effective treatment for hematological and non-hematological lifethreatening pediatric diseases. Both relapse and transplantrelated mortality (TRM) represent major obstacles for the cure of these pathologies by SCT. Therefore, one of the main objectives of transplant teams is to reduce TRM in order to improve long term survival. Objectives: To analyze TRM and overall survival (OS) changes over the years in pediatric patients receiving HSCT in a single center. Patients and Method: From June 1998 to October 2002, 156 consecutive children were treated by SCT (105 males/51 females). Median age: 10 years (2-18). Diagnosis were ALL (69), AML (33), NHL (8), HD (6), MDS (4), CML (3), SAA (8), PNH (1), Fanconi Anemia (5), Thalassemia (3), Ewing Sarcoma (9), Neuroectodermal tumor (1) and Neuroblastoma (6). Transplant modalities were: 100 autologous and 56 allogeneic (42 from an HLA-id sibling donor and 14 from alternative -unrelated or mismatched family donor). The infused product was bone marrow in 95 cases, peripheral blood in 58, both in 2 cases and cord blood in one. Median follow-up: 18 months (1-160). The target variables were analyzed in two different periods to be compared: from June'89 to the end of 1998, and from 1999 to October'02, and grouped according to the different SCT modalities. Statistical tests applied were Fisher's Exact Test and Kaplan-Meier Survival Curve. Results: Autologous TRM showed a statistically significant improvement within 1999-2002 (0%), compared to 1989-1998 (12'2%) (p<0.05), while no statistical differences were found in the allogeneic modalities. OS was 34% in the first period and 80'4% in the second period (p<0.01). This improvement was observed for all SCT modalities: Autologous (40'6% vs 93'5%); allogeneic HLA-id sibling (25% vs 64%) and allogeneic alternative donors (12'5% vs 50%). Conclusions: 1.-In our study, TRM significantly decreased for those children receiving autologous SCT in recent years. 2.-OS was significantly better in the latter period (1999) (2000) (2001) (2002) , both globally and for each SCT modality.
P776 Bone marrow transplantation for Fanconi's anemia: a retrospective review of The Tunisian experience
L. Torjeman, T. Ben Othman, S. Ladeb, A. Abdelkefi, A. Ben Abdeladhim (Tunis, TN)
We report the results obtained in sixteen patients with Fanconi's anaemia (FA), who underwent bone marrow transplantation (BMT) from HLA-matched related donors between february 1998 and october 2002. FA was documented by cytogenetic studies in all cases. Patients and methods: median age at BMT was 10 years (range,3-22) .
Conditioning consisted of low-dose cyclophosphamid (40mg/kg) and busulfan (6mg/kg) with the addition of lymphoglobuline (20mg/kg) in 2 patients (presence of HLA antibodies in 1 patient and in case of BMT from HLAidentical mother in an other patient). GVHD prophylaxis consisted of cyclosporin A and short MTX (5mg/m² at day1,3 and 6). The median MNC count was 3.32 x108/kg (range,1.27-5.2x108). Results: all patients engrafted (median, 12 days for an absolute neutrophil count> 0.5x109/l). Eleven patients (69%) are alive with sustained engraftment and are transfusion-independent at median follow-up of 13 months (range, 1 -43). Three patients (19%) developed graft failure at day 39,79 and 80 respectively after initial engraftment. One patient underwent unsuccessful second PBSC transplantation and is alive, 39 months with sustained engraftment after donor lymphocyte infusion. An other was died at d ay 0 of the second BMT. Two patients (12%) developed severe acute GVHD and died from invasive fungal infection and fatal CMV disease respectively. One patient developed chronic extensive GVHD and died from bronchiolitis obliterans. Conclusion : in our patients we observed a high incidence of graft failure. This may be explained by the relatively nonintensive conditioning regimen.
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Hematopoietic cell transplantation in children with MDSstill a challenge? K. Kalwak, D. Wójcik, E. Gorczynska, J. Toporski, D. Turkiewicz, M. Slociak, K. Pajdosz, P. Socha, A. Chybicka (Wroclaw, PL) Allogeneic haematopoietic cell transplantation (HCT) in children with MDS remains still a challenge due to toxic conditioning regimens given to minimize the risk of relapse or graft rejection in HLA-mismatched setting. Here we report the results of HCT in 17 children with different forms of MDS (JMML n=9; MDS-RA n=3, MDS-RARS n=1, MDS RAEB-t n= 4) transplanted in our institution. The major cytogenetic abnormalities included trisomy 8 and monosomy 7. Median time from diagnosis to HCT was 9 months (range 4 -90 months). The variety of HCT types included: allogeneic MSD-BMT (n=5), MUD-PBPCT (n=2), partially matched family donor (PMFD) T-cell replete BMT/PBPCT (n=6) and haploidentical Tcell depleted (TCD) PBPCT (n=4). In majority of cases the conditioning regimen consisted of busulphan, cyclophosphamide and melphalan. GvHD prophylaxis depended on HLA match and varied from CsA alone (1 mg/kg) to extensive T cell depletion in vitro (CliniMACS). Primary graft failure or graft rejection occurred in 5 patients having received HLA-mismatched grafts (T-cell replete n=3; T-cell depleted n=2). Second transplants resulted in 40% (2 of 5 pts) sustained engraftment rate; one of these pts (JMML, T-cell depleted graft after immune reconditioning with the use of Campath-1H) survives disease-free 100 days from the graft. The other pts with primary graft failure/rejection died due to: disease recurrence (n=1), sepsis (n=2) and cardiac insufficiency (n=1). In the patients who experienced primary sustained engraftment WBC > 1x109/L was observed on day +15 (median), ANC > 0.5x109/L on day +16 and platelets > 50x109/L on day +22, respectively. The causes of death in pts with primary engraftment were: GvHD (n=4), sepsis (n=1) and disease relapse (n=1). Altogether, 7 of 17 (41%) patients are surviving disease-free from 100 to 1878 days post transplant (mean 618 days). Among them there are 3/5 pts after MSD-BMT, 1/2 pts after MUD-PBPCT, 2/6 pts after PMFD T-cell replete HCT and 1/4 pts after TCD-PBPCT. Conclusions: 1. High rate of TRM in our series of pts results from the predominance of alternative transplants, including PMFD Tcell replete and haploidentical TCD-HCT. 2. The risk of graft rejection and/or GvHD may be reduced with the use of CAMPATH-1H in the HLA-mismatched setting, yet the impaired immune recovery should be regarded 3. Splenectomy prior to HCT may positively affect the posttransplant course in patients with overt splenomegaly.
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CMV-specific immune reconstitution in pediatric patients undergoing hematopoietic stem cell transplantation T. Lehrnbecher, W. Preiser, U. Köhl, G. Bauer, C. Fleckenstein, H.W. Doerr, T. Klingebiel, S. Buxbaum (Frankfurt/Main, D) CMV infection and disease still pose a significant problem in patients undergoing haematopoietic stem cell transplantation (HSCT). However, antiviral chemotherapy has a high toxicity. Since cell-mediated immunity is an essential host factor in control of CMV infection, an increased understanding of CMV specific immune reconstitution may help to improve treatment strategies. In the presented study, we monitor CMV-seropositive paediatric patients undergoing autologous or allogeneic HSCT weekly for immune reconstitution by determination of T -cell subsets, NK-cells and B -cells in peripheral blood samples. Analyses are performed by four-colour flow cytometry using CD45/CD4/CD8/CD3 and CD45/CD56/CD19/CD3 labelled with FITC/PE/ECD/PC5. In addition, plasma samples are tested for the presence of CMV DNA by a fully controlled real-time PCR (TaqMan). Every four weeks, we also enumerate CMV-specific CD4 lymphocytes by means of a rapid whole blood method. Stimulation employs whole CMV lysate antigen. Cells are stained for intracellular IFN-gamma produced by antigen-specific cells as well as for CD4 and CD69 as phenotypic and activation marker, which is assessed by multiparameter flow cytometry. To date, five consecutive patients have been monitored up to 6 months post-transplantation. Patients suffering from thalassaemia (n=1), relapsed ALL (n=2) and AML (n=1) underwent allogeneic bone marrow (n=3) or peripheral stem cell (n=1) transplantation. All donors were CMV-positive. One patient with rhabdomyosarcoma underwent autologous HSCT. In all patients, NK cell peak occurred during the first 4-7 weeks after transplantation, followed by a steep rise in T cells with a low CD4/CD8 ratio. Four patients were CMV DNA negative throughout, and between 1 and 33 CMV-specific CD4-lymphocytes/µl were detected on day +30. One patient, however, reactivated CMV on day +12 and remained CMV PCR positive despite antiviral treatment. He reached a maximum level of 34,000 CMV DNA copies/ml one month later. Cellular CMV immunity was not measurable at that time. Unfortunately, he was lost for follow-up. Our preliminary results underline the importance of specific cellular immunity to prevent CMV reactivation. The assessment of CMV-specific cellular immunity might help to define patients at highest risk for CMV reactivation, and to stratify patients with CMV reactivation in those who respond to antiviral treatment alone and those who might benefit from adoptive immunotherapy.
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Immune reconstitution and outcome after bone marrow and cord blood transplantation: a single pediatric institution experience
The recovery of a functional immune system following allogeneic bone marrow and cord blood transplantation is essential for the long term success of this treatment .The aim of this study was to evaluate the pattern of immune reconstitution in children after fully matched sibling marrow or cord blood cell transplantation. Between November 1997-November 2002 immunological reconstitution was analysed in n ineteen children allografted either by matched sibling marrow (n:17) or cord blood(n:2) progenitors. Among bone marrow allografted seventeen patients (7 girls, 10 boys) 7 were AML in 1 st remission while remaining others have different diagnosis (1 SCID, 1 WAS, 1 FAA,2 SAA,1 JKMML,1 SCA, 3 Thal). The age range was 6 months-17 years with a median of 10 years. Cord blood progenitor recipients (n:2)were both patients with Beta-Thalassemia Major (a girl-2.5 years; a boy-4.5 years old).Peripheral blood (PB) lymphocyte regeneration was investigated prior and at hematological reconstitution whenever achieved and at 2,3, 6,12,18 and 24 month following transplant.The distribution of lymphocyte subsets expressing CD3,CD4,CD8,CD45RA,CD45RO,CD19,CD56 and CD16 were evaluated by using direct immunofluorescence method and dual color staining in flow cytometry (EPICS XL-MCL).NK cells and CD8+ T cells were the first two populations which came up early after allogenic marrow transplantation. NK cells and CD8+ cells remained as the prominent populations till 3 and 12 post transplant months respectively. However CD4+ T cells were reached to reasonable levels by 12 month and B lymphocyte numbers seemed to be normalised at 6 months after transplantaion in marrow recipients.Early recovery of CD8+ T cells , NK cells and faster CD4+ T and B lymphocyte reconstitution have been detected in patients who had received cord blood cell transplantaion.All the patients except one are alive and well , after a minimum follow-up period of 7 months (range 7 months-5 years, median 18 months). One patient died 3 years after BMT with relapse of AML.
P780
Liposomal amphotericin B (AmBisome™) and caspofungin™ as combination therapy for suspected invasive fungal infection in children receiving chemotherapy or undergoing hematopoietic stem cell transplantation T. Lehrnbecher, Z. Elanjikal, J. Sörensen, H. Grüttner, H. Schmidt, T. Klingebiel (Frankfurt/Main, D) Invasive fungal infection remains an important cause of morbidity and mortality in paediatric cancer patients, in particular in those undergoing allogeneic haematopoietic stem cell transplantation (HSCT). Amphotericin B has been the cornerstone of systemic chemotherapy for invasive fungal infection, but new antimycotic agents, such as Caspofungin™, which is a member of the echinocandins, offer new therapeutic alternatives. However, despite extensive in vitro and animal studies of this drug, few clinical data have been published to date, in particular in paediatric patients. We report on three patients (2, 7, and 12 years of age) with suspected or proven invasive fungal infection. Two patients had undergone allogeneic HSCT, one patient had been diagnosed with invasive pulmonary and hepatic aspergillosis early during induction therapy for ALL. In all three patients, a rapid decrease of the size and the number of the pulmonary infiltrates was seen with a therapeutic regimen consisting of liposomal amphotericin B (AmBisome™ 5 mg/kg/d) and Caspofungin™ (loading dose 2 mg/kg, followed by 1.5 mg/kg daily). Interestingly, two of the patients showed an increase of the size and the number of the pulmonary infiltrates when using AmBisome™ alone (5 mg/kg/d), and in one patient, monotherapy with Caspofungin™ had no effect on the radiologic findings. All patients were long-term immunosuppressed either by chemotherapy or by a relapse of the hematologic malignancy. The patients received the combination therapy with AmBisome™ and Caspofungin™ over a period of 12, 28 and 140 days, respectively. No clinical side effects such as fever, nausea and flushing were noted. No laboratory abnormalities such as an increase in liver enzymes or bilirubin were seen, and temporary loss of potassium was clearly attributable to amphotericin B. We conclude that combination therapy with AmBisome™ and Caspofungin™ could be a useful treatment option in children with invasive fungal disease, even in very young paediatric patients. In two of the reported patients, combination therapy was more effective compared to monotherapy with AmBisome™ or Caspofungin™ alone. In addition, Caspofunginv given alone or in combination with AmBisome™ was well tolerated in our patients, even when given over an extended period of time.
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FTBI plus etoposide on day -3 versus FTBI plus etoposide on day -4 as preparative regimen for bone marrow transplant from matched sibling donor in children with ALL in II CR D. Boruczkowski, J. Wachowiak, A. Pieczonka, M. Leda (Poznan, PL) Nowadays the preparative regimen (prep-reg) consisted of FTBI 12 Gy (days -7 to -4) and etoposide (VP) 60 mg/kg (day -3) is the most recomended one in children with ALL (Dopfer et al., 1991) . However, even in children conditioned with this prep-reg leukemia relapse occurs in 40-50% cases. In 2002 we reported the data demonstrating that in some children given VP on day -3 the free fraction of the drug is still high on day of bone marrow transplant (BMT) (day "0") (Skibiñska et al.) . Therefore, to preserve the GvL effector cells contained in transplanted bone marrow from the cytotoxic effect of VP we decided to give VP one day earlier, i.e. on day -4 before transplantation. Between 1995-2002 thirteen children with ALL in II CR underwent allogeneic BMT from HLA-identical sibling. The median age was 9,5 years (range 5,5-12,5). All patients were conditioned for BMT with fractionated total body irradiation (FTBI) given at a total dose of 12,6 Gy in 8 fractions during 4 consecutive days (2 fractions/day) with reduction to 9,4 Gy in lungs. FTBI was followed by VP 60 mg/kg i.v. given on day -3 before BMT in 6 pts (Group VP-3) and on day -4 in remaining 7 children (Group VP-4). For GvHD prevention cyclosporin (CsA) alone was administered in 10 pts, CsA and "short" methotrexate (MTX) in 2 pts, and CsA plus prednisone (PRED) for 2 weeks in one. CsA whole blood level was monitored 3 x weekly and CsA dosage was adjusted to maintain its level of 100 +/-25 ng/ml until day 120 and then slowly tapered. Engraftment was achieved in all pts. Acute GvHD = II0 occured in one child from Group VP-3, and in 2 pts from Group VP-4 with subsequent extensive chronic GvHD in one child from each group. Among 6 children given VP on day -3 relapse occured in 3 of them. Three pts from this group remain in CCR lasting 2, 3, and 27 months with 25% pLFS after 2 years and 3 months. On the contrary, all seven patients given VP on day -4 are alive in CCR with median follow-up of 26 months (range 5-64) and pLFS of 100% at 5 years and 4 months (p<0,05). According to our preliminary observation the antileukemic effect of allogeneic BMT in children with ALL in II CR could be significantly improved, when VP is given on day -4 instead of day -3 before transplantation. Supported by grant KBN 4 PO5E 108 18
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Antimicrobial prophylaxis and microbial flora in children undergoing allogeneic bone marrow transplantation from HLA-matched sibling -11-year experience M. Leda, J. Wachowiak, D. Boruczkowski, A. Pieczonka (Poznan, PL) Bacterial and fungal infections continue to account for significant morbidity and mortality in HSCT recipients. Optimal management has to take into consideration the two competing priorities: lowering morbidity and mortality vs rising rates of microorganisms resistance and emergence of unexpected pathogens. We retrospectively analyzed microbial flora of the oral cavity (924 swabs) and the gastrointestinal tract (840 aerobic stool culture and rectal swabs). Specimens were taken every week from 106 children, who underwent allogeneic HSCT in our unit between 1989-2001 (indications: ALL=42, AML=26, CML=18, SAA=13, others 7; age 2 ¨C18 years, median 10; 56 male, 50 female). All patients had an HLA identical family donor and in all but one cases bone marrow was the source of SC. All patients performed mouthrinse with 0,1% chlorhexidine solution 3 times daily and at least one topical antifungal agent was applied on a routine basis. Based on admission set of microbial flora studies all children were given at least one oral nonabsorbable antibiotic (colistin, neomycin, gentamycin) and at least one antifungal (nystatin, oral amphotericin or flukonazole) from the admission until their dismissal from the hospital. Vancomycin was given only when it was required by susceptibility tests (in 36 pts; 34%). Whenever an infection was suspected, parenteral therapy based on the recent culture results was started. We achieved transient decontamination (from day +1 till +14) in 57% and 47% of children in the mouth and gastrointestinal tract, respectively. We also found that stomatitis grade II (ac. Bearman) occurs in 8% of pts, who were successfully decontamineted, but in 22% pts who were not. We did not notice any significant changes in rates bacteria and fungi occurrence in mouth and GI. (exceptions are: decline of Candida sp. from mouth and GI and increase in CONS at the expense of St. aureus in mouth). Moreover, we observed neither increase in occurrence of such pathogens as Pseudomonas sp., Stenotrophomonas sp. Enterococcus sp. nor change in pathogens resistance to antibiotics. We did not note any death attributable to a microorganism from our ward. We conclude that antibacterial and antifungal prophylaxis in children is still a reasonable option.
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Chimerism: predictive value of early complete donorengraftment for long-term outcome after allogenic stem cell transplantation R.F. Sharon, M. Tilanus, T. Révész, R. de Weger, N. Wulffraat, M. Bierings (Utrecht, NL) Introduction: Stem cell transplantation (SCT) is preferred therapy for several malignant and severe benign hematological diseases, as well as immunological disorders in children.Early indicators of imminent morbidity are urgently needed. Aim: Evaluation of chimaerism as predictor for morbidity and mortality after SCT.
Methods: 48 transplantations in children between the years 1996 and 2000 were analysed. 25 SCTs were for malignancies, 7 for benign hematological diseases and 16 for immunological disorders. The outcome parameters were survival, disease recurrence and non-engraftment. Chimaerism data were analysed using PCR of 4-bp short tandem repeats in DNA of peripheral blood leucocytes. The patients were divided into 2 groups: malignant and non-malignant. Results: 2 weeks post-transplant there was no engraftment in 12 patients in the malignant group. Of those 4 died (33%). Of the remaining 13 patients 5 patients had a chimaerism of 100% donor, of which 1 died as a result of an infection. 8 patients had a mixed chimaerism at 2 weeks post-SCT, of which 6 died. The causes of death in these 6 patients were relapse (n=3), infections/sepsis (n=2) and GvHD (n=1).In the non-malignant group 14 out of 23 patients did not have any leukocytes 2 weeks post-SCT. In that group 3 died (21%). Of the remaining 9 patients all 6 patients with 100% donor at 2 weeks survived without complication. 2 patients had a chimaerism of 80% donor, but survived without complications.1 patient had 0% donor. He was transplanted for a second time, but persistently had 0% donor. He subsequently died. The analysis of chimerism studies later after transplant does not allow prediction of imminent morbidity, mainly due to small groups. Conclusion: Chimaerism 2 weeks post-SCT in both malignant and serious non-malignant pediatric diseases is a predictor for the outcome after allogenic BMT: with 100% donor early after transplantation the chances of eventual non-engraftment and recurrence of disease are minimal.Patients who do not have 100% donor 2 weeks post-BMT could possibly benefit from reduced immunosuppression.This remains to be investigated however.
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Hematopoietic stem cell transplantation for rare congenital diseases were A,B,DRB1 matched, while 7 were 1 antigen mismatched. Five children (1 undergoing MSDT and 4 undergoing MUDT) were given a preparative regimen including radiotherapy. Most remaining children were conditioned with a chemotherapy regimen which included Busulphan and Cyclophosphamide alone for MSDT, associated with TT for MUDT. GvHD prophylaxis included CSA alone in most MSDT patients, while most MUDT patients were given CSA and "short" MTX associated with ATG or "in vivo" Campath 1G. Actuarial 5 year survival was 75% and 74% for MSDT patients and for MUDT patients, respectively. No difference was observed in GvHD incidence and in TRM r ate between patients given MSDT and patients given MUDT. Conclusions: MUD transplant represents an attractive option for children with rare congenital diseases lacking MSD. Extensive DNA matching, 3-drug preparative regimen and GvHD prophylaxis including ATG in MUDT patients gave similar results to those achieved in MSDT patients. Partially supported by Ricerca Finalizzata Ministeriale 2002, Compagnia di San Paolo e Fondazione CaRiGe.
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Severe neurological complications after bone marrow transplantation in children D. Uckan, M. Cetin, I. Yigitkanly, I. Tezcan, M. Tuncer, D. Karasimav, D. Yalnyzoolu, M. Topcu (Ankara, TR) Neurological complications may occur in bone marrow transplantation (BMT) recipients (11-39%), frequently contributing to morbidity or mortality and are the main cause of death in 10% to 15%. Life threatening neurological complications were seen in 10 out of 112 (9%) children who underwent allogeneic BMT for hematological, immunologic and metabolic diseases. The ages of the patients ranged from 2 to 16 yrs. Six patients received bone marrow or PBSCT from HLA-matched sibling donors, three from mismatched family donors. One patient received unrelated HLA 5/6 matched umbilical cord blood. All patients except 18 with SCID received conditioning with immunosuppressive +/-myeloablative regimens. Cyclosporin A(CsA) and methotrexate was used for GvHD prophylaxis. The diagnoses of patients with neurological complications were AML(5), Thalassemia Major (2), Fanconi anemia (1), Omenn syndrome (1) and globoid cell leukodystrophy (GLD) (1) and the neurological events were seen between days -4 to day +85 after transplantation. All patients except one with GLD were free of neurological symptoms before transplant. Minor symptoms such as mild headache and tremors were excluded. The most common complication was due to CsA toxicity and was seen in 4 patients presenting with cortical blindness, generalized convulsion, visual abnormalities and motor signs. EEG abnormalities were present in all and included epileptiform discharges or focal slowing. MRI findings were supportive of the diagnosis with leukoencephalopathy involving the occipital lobe. The rest of the complications were; brain abscess/ meningoencephalitis (2), severe hypomagnesemia (1), busulfan toxicity (1), hypertension, intracranial hemorrhage (2) which initially presented with headache, convulsions and/or cranial nerve palsies. Four patients were suffering from grade III-IV GvHD when they developed neurological complications. In this study including a small group of patients, the pre-transplant stage of the disease, intensive prior treatment and grade III-IV GvHD were important adverse factors for development of severe neurological complications and CsA toxicity was a major factor.
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Bone marrow transplantation for myelodysplastic syndromes in childhood: results on 34 patients from a single center E.T. Korthof, P.P. Snijder, M. Oudshoorn, J.L. Lie, J.M. Vossen, R.M. Egeler (Leiden, NL) Allogeneic stem cell transplantation is the only curative therapy for children with myelodysplastic syndromes (MDS). We present single center data on 34 MDS patients (pts) transplanted over a 20 year period . Patient characteristics: 23 males, 11 females (ratio 1.9) aged 0.0-118.2 yrs (median 9.5 yrs) at diagnosis. Karyotype was abnormal in 23 cases (monosomy 7 in 12). In 19 cases intensive ANLL chemotherapy of different duration was given before BMT. An HLA-matched sibling donor (ID) was used in 17 cases, another phenotypically identical related donor ( Results: a stable engraftment was observed in 29/34 cases (1/34 cases early relapse, 2/34 cases take failure, 2/34 cases rejection). Complications occurred in 18 cases: VOD (n=3, mild); 5 infectious complications (2 pts died from Asp. pneum); EBV-LPS (n=3, one pt died). Diabetes insipidus occurred in 2 cases. In 5 cases acute GVHD grade II occurred; chronic GVHD of skin and liver was seen in 3 cases. Relapse occurred in 5 cases, at a time range from 3 to 56 months after BMT. All pts died of their relapse.A second BMT was not performed in case of relapse; for the 4 pts with take failure or rejection a second BMT was performed without success: all 4 pts died of infectious complications. The follow-up for 22 surviving pts ranges from 2.0 yrs to 20.3 yrs (med. 6.0 yrs). Late effects include hypothyroidism (3), herpes zoster infection (6). Conclusions: Of the 34 patients transplanted for MDS, 22 patients are still alive and free of disease. Transplant toxicity and/or infections resulted in death in 7 children, relapse was the cause of death in 5 children.
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Stenotrophomonas maltophilia infection of the central venous catheter and lysis of an old blood clot in a post BMT patient: implications in the fibrinolytic process D. Uckan, S. Kirazli, D. Gür, M. Demirci, D. Akata, G. Balta, N. Sayýnalp, C. Akyüz (Ankara, TR) Central venous catheter use is frequently associated with thrombotic events and management and lysis of a catheterrelated blood clot may be problematic. An 11 yr old girl with relapsed NHL developed a large thrombus in her right juguler vein at day + 10 after BMT from her HLA-identical sibling. The Doppler U/S revealed the thrombus to be 10 cm in length, interfering totally with blood flow around the catheter and extending to superior vena cava at the right atrium inlet. The analysis of Factor V Leiden, Prothrombin G20210A, MTHFR CG777 and PAI-1 gene 4G/5G genotypes and hypercoagulability tests failed to show an underlying predisposing factor for development of the thrombotic process. The patient experienced 3 mild attacks of pulmonary symptoms consisting of dry cough, tachpnea and mild dyspnea that were relieved by administration of oxygen. The imaging studies were suggestive of pulmonary emboli. Because of the severely thrombocytopenic state and increased bleeding tendency, a thrombolytic agent was not administered. The catheter was not removed due to the risk of massive emboli during removal and the necessity to continue its use.The patient was managed conservatively and placed on low molecular weight heparin and did not experience further adverse events. Four months later she was about to undergo surgical removal of the catheter when she developed catheter-related Stenotrophomonas maltophilia infection (SM) . Interestingly, the repeat Doppler study failed to show a thrombus any more and revealed a normalized blood flow. We hypothesized that a massive load of bacteria on the blood clot per se might have induced complete lysis, perhaps by secreting fibrinolysin. Pulmonary hemorrhage has occasionally been described in the literature in patients suffering from SM infection and in a recent article has been attributed to a bacterial protease inducing tissue damage. In order to test the contributary role of fibrinolysis in the occurrence of hemorrhagic complications and clot lysis in the present case, the global fibrinolytic capacity was tested in vitro using SM cultures and other control bacteria. Fibrinolytic activity of SM was demonstrated. Based on the present clinical observation and supporting in-vitro evidence of fibrinolysis we suggest that SM bacteria may carry fibrinolytic properties that may have clinical implications.
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The immune dysregulation, polydocrinopathy, enteropathy, X-linked syndrome (IPEX) B. Birkenau, A. Schwarzl, W. Kail, S. Matthes, C. Peters, H. Gadner (Vienna, A) The immune dysregulation, polyendocrinopathy, enteropathy, Xlinked syndrome (IPEX) is a recessive disorder of early childhood. Symptoms of the disease generally appear in infancy and include protracted diarrhoea, ichthyosiform dermatitis, insulin-dependent diabetes mellitus, thyroiditis and haemolytic anaemia. So far patients with IPEX syndrome have only been treated with supportive (total parenteral nutrition, insulin and blood transfusion) and immunosuppressive (cyclosporin and steroids) therapy. Unfortunately the prognosis for these patients is extremely bad. Most of the few patients reported on died before their first birthday. The only promising therapy is haematopoietic stem cell transplantation. Only 2 children with IPEX have been transplanted worldwide. One of them, patient M.E., was transplanted in our institution. For this little patient an HLA-identical unrelated donor was available, and he was transplanted with CD34+ selected PBSC at the age of 9 months. The child's condition was poor before PSCT. He suffered from a variety of complex clinical symptoms (insulindependent diabetes, intractable diarrhoea, dystrophy, eczemas, MRSA-sepsis and severe immune deficiency), the combination of which required a high degree of commitment and flexibility from the doctors and nurses caring for this patient. With our patient documentation according to OREM we would like to demonstrate, how we planned, organised and performed the care for this patient, who was particularly vulnerable to toxicity and infectious complications. At the moment our little patient is catching up with his development and recovering from his nutrition deficits. The successful transplantation has smoothed the way for this patient's development into a healthy infant. On day +72 he could be released home from hospital.
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Familial hemophagocytic lymphohistiocytosis: successfull haplo-identical stem cell transplantation A. Lawitschka, S. Matthes, G. Mann, G. Fritsch, H. Gadner, C. Peters (Vienna, A) Hemophagocytic lymphohistiocytosis (HLH) comprises familial (FHL) and secondary (SHLH) haemophagocytic lymphohistioctosis, both characterised by fever, hepatosplenomegaly and cytopenia. FHL, an autosomal recessive disease invariably fatal when untreated, is associated with defective triggering of apoptosis and reduced cytotoxic activity, resulting in a widespread accumulation of activated macrophages and T -lymphocytes. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for FHL. Most published data are derived from HSCT using HLAidentical family or matched unrelated donors and there is only limited experience with grafts from haploidentical family donors. We describe haploidentical HSCT in a b oy presenting with extensive FHL (lacking perforin expression). Initial treatment according to HLH-94 study protocol (etoposid, dexamethason, cyclosporin A) led to complete clinical response after 2 months. Due to recurrent disease with CNS-involvement and the lack of a matched donor the boy underwent allogeneic PSCT from the haploidentical (2 AG mm) mother 2.5 months after relapse. The conditioning regimen consisted of 180 mg/m2(6x30) fludarabine, 8mg/kg (4x2) busulfan, 140mg/m² melphalan and 7,5mg/kg(3x2,5) ATG rabbit. 29 x10*6 CD34 cells and 3 x10*4 CD3 cells per kg of the recipient were transfused. GvHD and rejection prophylaxis consisted of CsA(day +20 till day+ 96) and MMF(day +20 till day +47). Intrathecal methotrexat was given 6 x 6mg during SCT course. Myeloid engraftment with ANC>0,5 G/L was achieved on day +12 and stable T-cell engraftment on day +130. Chimerism analyses were performed on FACS-sorted cells by FISH and showed full donor chimerism from day +20 on. Transplant related toxicity was severe (skin, lung, gut) but transient. Infectious complications were short febrile neutropenia and enterosepsis. 1.5 years after SCT the pt. presents with no evidence of HLH or GvHD and excellent psychomotoric development with a Lansky score of 100%. For children with FHL lacking a matched donor, haploidentical HSCT is an important alternative treatment option. Early HSCT should avoid recurrent disease and reduce organ toxicity in these pts. Engraftment can be achieved even in the haploidentical HSCT setting with reduced intensity conditioning.
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Megadose of activated natural killer cells using KIR epitope incompatibility for pediatric patients after haplo-identical transplantation in leukemic blast persistence U. Koehl, R. Esser, S.Y. Zimmermann, H.P. Grüttner, J. Sörensen, T. Bartling, H. Martin, P. Lang, C. Seidl, T. Tonn, E. Seifried, T. Klingebiel, D. Schwabe (Frankfurt, Tuebingen, D)
Patients with blast persistence in therapy refractory or multiply relapsed leukemia still remain incurable. A benefit of early NK reconstitution for patients with AML, but not ALL, after haploidentical stem cell transplantation (HTx) in remission when KIR epitope incompatibility is in the GvH direction has been demonstrated (Ruggeri et al, Science 02). No differences were found in 175 patients transplanted from 1 -3 loci mismatched unrelated donors between those with and without KIR ligand incompatibility and between different diagnosis groups (Davies et al, Blood 02). However, graft preparation differed from the Italian group. We sought to make use of a possible benefit of directed KIR mismatches after HTx in patients with blast persistence. In a feasibility trial we treated 3 pediatric patients (1 AML, 2 ALL) in blast crisis with HTx followed by infusions of megadose (3-34x10^6/kg) purified lymphokine-activated donor NK-cells (LANK) every 4 weeks starting on day 1 of HTx. All patients suffered from 2nd or 3rd relapse refractory to chemotherapy with 37-97% leukemic blasts in bone marrow samples before graft infusion. Patients were transplanted from parental donors with 5.5-35.7x10^6CD34+/kg and <22x10^3CD3+/kg. NK cells were enriched from unstimulated PBSC by two CD3+ depletion steps with a final CD56 enrichment step on the Miltenyi CliniMacs. A median purity of 96.9% CD56+CD3-with <0,08% CD3+ was reached. IL-2 stimulation resulted in maximum cytotoxic activity against the patients´ leukemic blasts after 10-12 days as determined by a Europium assay or a flow cytometric assay on a 3-or 4 -colored Coulter EPICS XL-MCL. Directed KIR mismatches were demonstrated for both ALL patients (KIR2DL1) and the AML patient (KIR2DL2/3 and KIR3DL2). Neutrophils engrafted on days 11-14. LANK therapy was tolerated well. All patients reached complete remission first documented one month post HTx. I n one of the patients with ALL, complete remission lasted until day +152 with >99% donor chimerism, when the patient died of atypical pneumonia due to parvo B19 virus infection. The second ALL patient died early on day +45 of VOD. The patient with AML relapsed on day +64 and died on day +80. We conclude the feasibility of repetitive megadose LANKimmunotherapy in the context of directed KIR epitope incompatibility, which may be a new treatment option for pediatric patients with leukemia in case of MRD or imbalanced chimerism post HTx.
P791
Intensive care unit admissions and clinical outcome of children undergoing stem cell transplantation: 11-year experience in a reference hospital J. Aliaga, J.M. Fernández, A. Verdeguer, R. Sanchis, A. Cañete, V. Castel (Valencia, E) Objective: To evaluate the need of intensive support and clinical outcome in a cohort of children undergoing stem cell transplantation in a reference hospital Patients and methods:161 stem cell transplants have been performed in our Unit between January 1992 and November 2002 (10 years, 11 months). 118 were autologous and 43 allogeneic, including 7 umbilical cord blood transplants. We retrospectively reviewed the charts of the patients admitted in the intensive care unit at any time from conditioning until day +100 . Results: Twenty patients (12.4% of the total) needed intensive support in 21 occasions. Median age was 4 years (1-15), and 12 were boys. The underlying diagnosis was leukemia or lymphoma in 13 cases and solid tumor (mostly neuroblastoma and medulloblastoma) in 7. Eight patients were transplanted in their first CR. The rest (12) underwent transplant with more advanced disease (CR>2=7,PD=5). Eleven out of 43 allogeneic transplants (25.5%) (5/7 CBT), and 9/118 autologous (7.6%) required ICU admission (p<0.005). TBI was part of conditioning regimen in 5/21 procedures. Respiratory failure was the major reason for admission to ICU (14/21, 66.6%) followed by neurological disturbances (4/21, 19%). Most of ICU requirements in our series did occur between day 0 and day + 25 (19/21, 90.4%). Our patients remain in the ICU for an average of 5.5 days, median=2(1-16)days. Nineteen out of 21 required mechanical ventilation (mean=5,3 days, median=3, range=1-15) and 13/19 died (68.4%). Two patients did not need respiratory support and both recovered. Patients with multiorganic failure (MOF)were intubated for 7 days (median) versus 3 days in the rest of children. Thirteen out of 20 patients died in the ICU (65%):Nine due to MOF, 3 to respiratory failure and one to cardiac failure. Most exitus (9/13) had leukemia or lymphoma and 6/13 were in their first complete remission. All the patients admitted in the ICU for neurologic disturbances recovered. Seven patients were discharged from the ICU but 4 died thereafter, before d+180. Three are still alive with 9, 15 and 35 months follow up. Conclusions: The need of ICU admission in our series does not differ from previous reports. Respiratory failure is the main reason and mortality in this group of patients is very high. Nevertheless, intensive support can be live-saving for some patients (mostly for those admitted for neurological disturbances).
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Successful hematopoietic stem cell transplantation in pediatric high-risk refractory Langerhans cell histiocytosis M. Caniglia, R.M. Pinto, I. Rana, A. Lombardi, R. Caruso, W. Arcese, G. De Rossi (Rome, I)
The clinical course of LCH ranges from spontaneous regression to chronic and sometimes lethal disease with a short life expectancy.A small number of patients,frequently yungher than 2 years of age,with multisystem disease (MDS),vital organ dysfunction and rapid disease progression are considered to have a poor prognosis despite various treatments with cytotoxyic drugs and steroids either alone or in combination. The non response patients after 12 weeks of therapy,identifies High Risk (HR) patients with a probability of fatal outcome of 75% and a chance of becoming disease free less than 20%.Hematopoietic Stem Cell Transplantation (HSCT) is therapeutical option rarely proposed that may however offer an opportunity for long-term remission and disease free survival. In this report we describe two young patients (5 months old) both presenting rapid MSD progression despite chemotherapy with single or multiple agents or immunosuppressive therapy.Allogeneic HSCT was performed 10 and 23 months respectively from diagnosis.Patient 1 received Umbelical Cord Bood Transplant (UCBT) from un HLA 4/6 m.matched unrelated donor. Patient 2 received a Bone Marrow Transplant (BMT) from his related HLA identical donor. Conditioning regimen was the same in both patients consisting with Busulfan 4mg/kg and Fludarabine 30mg/m2 from day-7 to day-4 and Thiotepa 10mg/kg on day -3 ; both recived ATG 15mg/kg from day-5 to day -2 .GVHD prophylaxis was CSA 1mg /kg from day -7 to day -2 and 3 mg/kg from day -1 to day + 180. PDN was administered 1mg/kg/day until day + 30. Engraftment was demonstrated by PCR DNA analysis and a progressive improvement of disease signs and symptoms was observed after 16 and 9 months. Patient 1 presented a severe myelofibrosis before HSCT that reversed 14 months after HSCT. We concluded that HSCT could be the appropriate treatment for this poor-prognostic patients as well as in LCH patients with aggressive active disease. UCBT could be considered in the treatment of patients with chemotherapy-resistant progressive LCH, expecially if HLA matched family donors are not available. These preliminary results need a further confirmation
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Kinetic study of CD 34+ cells and safety of large volume leukapheresis in low weight children E. Lydaki, I. Bolonaki, I. Nikoloudi, M. Niniraki, K. Katsanoulas, D. Mavroudis, H. Dimitriou, E. Stiakaki, G. Martimianaki, M. Kalmanti (Heraklion, GR)
Twenty one children mobilized with chemotherapy and G-CSF underwent 47 apheresis, 24 of which in low weight (LW) children using the CS-3000 Plus blood separator. Collections were performed using two different protocols depending on the total blood volume (TBV) processed: standard volume leukapheresis (SVL< 3 times TBV, n=23) and large volume leukapheresis (LVL)(>3 times TBV, n=20). All LVL were performed in LW children. Blood priming was performed in LW children when estimated that the extracorporeal volume would be >25% of TBV or Ht would decrease <25% during collection. Calcium gluconate (50mg/kg) was administered in all LVL. The inlet flow rate, collection time, recruitment and collection efficiency of CD 34+ cells, blood counts and CD34+ cells in the peripheral blood after each blood volume were measured. Evaluation of CFU-GM development and replating capacity (with AUC assay which provides a measure of replication of myeloid progenitors as a whole) were also estimated during the apheresis procedure. Immediate adverse effects during apheresis were also recorded. Our results showed no differences in median CD34+ yield, (p=0.14), in CD34+ recruitment (p=0.4) or in collection efficiency (p=0.4) between LVL and SVL. There was no substantial difference in the clonogenicity or replating capacity at the different time points of evaluation. The threshold of 2x106 CD34+ cells per kg per collection was achieved more commonly in children of the LVL group as compared to SVL (p<0.001). Platelet loss, hyperphosphatemia and hypokalemia were common and more severe in the LVL than SVL group. In conclusion, we observed no trend of CD34+ cell recruitment and no clinically serious adverse events during LVL in LW children. However we recommend extra caution when performing LVL in LW children with low platelet count.
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Successful collection of peripheral blood stem cells from a four-month old infant with neuroblastoma and a body weight of 5700g
G. Kumlien, A. Losvall, A. Ayoub, L. Kanoogo, A. Shanwell (Stockholm, S) Background: The patient was born at full term with paraparesis and bladder paralysis. Neuroblastoma III with spinal growth was diagnosed and treatment was initiated five days post partum. At 3½ months the patient was referred to our department for collection of peripheral blood stem cells. Method: Apheresis was performed on three consecutive days when the patient was four months old and the body weight 5700g. Apheresis was performed using CobeSpectra apheresis machine and the automated program for mononuclear cell harvest AutoPBSC 6.1. A central dialysis catheter was used for the apheresis and a single line central venous catheter was used for administration of potassium and calcium because the child was to small for a porth a cath. The apheresis machine was primed with leukocyte depleted erytrocyte concentrate mixed with fresh frozen plasma to a hematocrite 5-10% above the patients current hematocrite and irradiated with 25 Gy. The estimated blood volume was 456 ml and thus the extracorporeal volume was more than 50% of the total blood volume. Twice the estimated blood volume was processed each procedure. The blood flow was 4.9 ml/min. Elektrolytes were carefully monitored and infusion of calcium and potassium was needed every procedure. ECG was monitored. Results: Yield of CD34+cells was 8,25 x 10(6) CD34+ cells/kg recipient. Conclusion: To our knowledge, this is the smallest child (<7 kg) reported to have undergone autologous peripheral blood stem cell collection1,2. Our experience shows that this can be a safe procedure with satisfactory yield of CD34+ cells. This also shows that a satisfactory yield of CD34+ cells can be achieved with a blood flow below what is recommended by the manufacturer (<10 ml/min). 
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Improved platelet recovery after transplantation of highly purified allogeneic CD133+ stem cells in children P. Lang, P. Bader, D. Niethammer, M. Schumm, M. Schwämmle, C. Jaki, C. Weinstock, S. Kuci, T. Feuchtinger, R. Handgretinger, J. Greil (Tuebingen, D) Immunomagnetic selection of CD34+ progenitor cells from alternative donors is a well established method, which can effectively prevent GvHD even in the haploidentical setting. Our aim was, to investigate whether selection of progenitor cells with the new stem cell marker CD133 would improve engraftment and in particular platelet recovery. Therefore, 7 patients with ALL (n=4), JMML (n=1), MDS (n=1) and Wiskott-Aldrich Syndrome were transplanted with a standard dose of CD34+ selected stem cells (median number = 15x10E6 cells/kg) from haploidentical related donors (n=6) or from matched unrelated donors (n=1). Moreover, 1 to 10x10E6/kg CD133+ selected stem cells were added to the graft. The number of residual T-cells in the whole grafts was <25.000 T -cells/kg. No GvHD >grade I and no adverse side effects were observed. Thrombocyte recovery was defined as independence from platelet transfusions for at least 14 days with platelet counts >20.000/µl for 3 days. The results of the CD34+/CD133+ group were compared to that of a historical control group from our institution (101 patients, who had received CD34+ selected grafts from alternative donors), using the Kaplan-Meier method: median thrombocyte recovery in the CD34+/CD133+ group was significantly faster than in the control group (14 vs. 37 days, p=0.02, logrank-test). Conclusions: CD133+ selected stem cells appear to improve thrombocyte regeneration compared to CD34+ selected cells. Combination of CD34+ and CD133+ selected grafts is a feasible method and the portion of CD133+ cells may be increased in the future. However, the number of patients is still low and further investigations have to be done to confirm these findings.
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Treatment of impeding relapse after allo-SCT with imatinib and DLIs in a Ph+-ALL patient on the basis of increasing mixed chimerism and MRD-levels G. Kerst, H. Kreyenberg, G. Duckers, G. Weber, K. Schilbach, P. Lang, J. Greil, D. Niethammer, P. Bader (Tuebingen, D) Introduction: A relapse after allogeneic bone marrow transplantation is the main reason for a treatment failure in patients with acute lymphoblastic leukemia. In contrast to CML patients who relapsed after allo-SCT, immunotherapy with DLIs is not an effective treatment in ALL-patients with a relapse after allo-SCT. However, in Ph+-ALL patients a preemptive therapy with imatinib and DLIs on the basis of increasing mixed chimerism and MRD is a rational approach for the prevention of frank relapse. Methods: Flow cytometric analysis of MRD was performed according to the protocols invented by E. Coustan-Smith and D. Campana (St. Jude Children´s Hospital, Memphis, TN). Patient specific junctional regions of rearranged immunoglobulin and Tcell receptor genes and the chromosome translocation product BCR-ABL were used as targets for real time PCR assays. Case report: We report on a 9 year old boy with a Ph-positive ALL. According to ALL-BFM 2000 he was treated in the high-risk arm and transplanted in first complete remission with the bone marrow of an HLA-matched sibling donor (1.4x10^8 TNC/kg). The conditioning regimen consisted of TBI (6 x 2 Gy) and etoposide (60 mg/kg). Cyclosporin A was given for GVHDprophylaxis. Engraftment occurred on day 15 for leukocytes (>1.0 x 10^9/l). While in morphological remission, MRD analysis revealed 2 x 10^-4 residual blast cells in the bone marrow 6 months and 2 -5 x 10^-2 leukemic blasts 8 months post transplant. At that time, chimerism analysis showed 5 -10% autologous cells in the bone marrow. Because of these findings, the patient received imatinib (10 mg/kg PO) and a total of 2.5x10^5 CD3+ cells/kg (fractionated in 4 doses). 4 months after the initiation of this therapy, MRD has fallen below 1 x 10^-4. To date, the patient has stayed in complete remission for 6 months after the initiation of therapy. Conclusion: Preemptive treatment by DLIs and imatinib on the basis of increasing MRD and mixed chimerism is a feasible approach in Ph+-ALL patients after allo-SCT to prevent frank relapse. This work was supported by the fortüne-Programm of the University of Tuebingen (G.K.), by the Deutsche Krebshilfe (P.B.) and the BMBF-IZKF IIA (P.B.).
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Boosts with highly purified stem cells following allogeneic transplantation from alternative donors P. Lang, J. Greil, M. Schumm, D. Niethammer, C. Braun, R. Handgretinger, T. Klingebiel, P.G. Schlegel, M. Pfeiffer, P. Bader (Tuebingen, D) Between 1999 and 2002, 87 pediatric patients with leukemias and various nonmalignant diseases have been transplanted with highly purified peripheral stem cells either from closely matched unrelated or from haploidentical related donors. Stem cells were purified with an immunomagnetic selection method using antiCD34 or antiCD133 coated microbeads. 29% of the patients received additional donations (boosts) with CD34 or CD133 selected progenitors in order to speed up engraftment or to improve insufficient hematopoesis after successful engraftment. Boosts were given without reconditioning and without any posttransplant pharmacological immunosuppression. Our aims were to improve engraftment and to maintain stable and complete hematopoiesis without inducing acute or chronic GvHD. A total of 40 boosts were given between 4 and 490 days after transplantation with a median number of 5 (0.6-34) x 10E6 CD34+/CD133+ progenitor cells/kg and only 2200 (100-25000) residual T -cells/kg. Patients received between one and four boosts. 9 patients were boosted between day 4 and day 16. After successful engraftment, 21 patients were boosted due to decreasing hematopoiesis (day 19 -498, median = 59 days). Acute GvHD >grade I and also chronic GvHD could be completely avoided even in haploidentical donors. All boosted patients achieved engraftment. In 80% of patients hematopoiesis was improved and stabilized (increasing leukocytes, erythrocytes and platelet counts). Furthermore, in 2 patients with increasing mixed chimerism, infusion of stem cell boosts led to a complete donor chimerism. Conclusions:.Boosts with purified stem cells and low T -cell contamination (<10000 T -cells/kg) can be administered after transplantation without the risk of inducing GvHD, even in mismatched donors. No pharmacological immunosuppression was necessary. Thus, the method represents a safe tool and may improve and stabilize complete donor derived hematopoiesis.
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VOD-prophylaxis using defibrotide during stem cell transplantation in children A.S. Schulz, Y. Chalandon, W. Friedrich, H. Ozsahin, T. Gungor, S. Corbacioglu (Ulm, D; Geneva, Zurich, CH) Hepatic veno-occlusive disease (HVOD) is a life threatening complication most frequently described in p atients receiving high-dose myeloablative chemotherapy for hematopoietic stem cell transplantation. HVOD is characterized by painful enlargement of the liver, fluid retention, weight gain and jaundice and it usually occurs within the first 4 weeks after transplantation. Current therapeutic and prophylactic options for HVOD are limited, of questionable benefit or are burdened with excessive toxicity. Defibrotide (DF) possesses anti-thrombotic, thrombolytic, anti-inflammatory and anti-ischemic properties without significant systemic side effects. Meanwhile it could be demonstrated in several studies that DF is an active therapeutic modality for HVOD. In a series of 26 pediatric patients treated with stem cell transplantation in three BMT centres we evaluated the feasibility of the prophylactic use of DF. The patients, aged between 3 months and 16 years were treated for malignant (n=10) and nonmalignant hemotologic disorders (n=16). The myeloablative conditioning regimen was Busulfan based in 17 cases. Donors were MRD (n=11), MUD (n=8), MMFD (n=6) and MMUD (n=1). Ten patients were considered as high risk patients to develop HVOD due to pre-existing liver disease (n=2), secondary transplants (n=3), osteopetrosis (n=1), prior treatment with Mylotarg (n=2) and macrophage activation syndromes (MAS, n=2). Prophylactic DF was given in a dose of 15 to 25 mg/kg/d starting the first day of conditioning until day +21 to +28 or until patients developed HVOD in which case the DF dose was increased. HVOD developed in three out of the 26 patients (11.5%). Two patients had a high risk for HVOD (prior Mylotarg treatment and chronic active Hepatitis C). Both developed moderate HVOD and recovered fully. The patient with no HVOD-specific risk factors suffered from CMV disease and severe GvHD and succumbed to multiorgan failure. Overall DF was tolerated very well. It was stopped in three patients. One of the patients with moderate HVOD developed intractable bleeding after aspiration of a pleural effusion while on therapeutic DF and two patients with prophylactic DF were stopped due plantar edema and tachycardia.
In conclusion, the prophylactic use of DF is a feasible approach in the context of stem cell transplantation in children. Inasmuch DF is a valid prophylactic tool for HVOD must be further evaluated in a controlled prospective study.
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Infections after pediatric stem cell transplantation: a single center experience G. Gedikoglu, H. Bilgen, S. Ozgenc, E. Can, H. Agirbasli, S. Kaya, S. Anak (Istanbul, TR) Infections are common and life threatening complications of SCT.In our single center we have evaluated the incidence,characteristics and outcome of infections during the SCT period.Between January 1998-June 2002 84 children(51 male,33 female) with a median age of 7(5 mo-18 years)recieved 87 SCT(62 Allo,25 Auto)with the various underlying diseases mainly AML (34%The duration of neutropenia was median 16 days(12-100 days).In 49/59 patients who had alloSCT a total 126 febrile attacks and in 19/25 (76%) patients total 43 febrile attacks were seen.In 169 febrile attacks 105 (62%) had microbiologically documented infections.Febrile neutropenic attacks were seen in 44 patients,46 had no neutropenia and 15 had no fever.The bacterial pathogens were isolated at median +21st day in 72.2%(52.9% Gram(+),47.1% Gram(-)) the Staph.Aureus consisted the 74% of the Gram+pathogens and Pseudomonas consisted the 45% of the gram(-) pathogens.The fungal infections were seen in 21% of the patients at median +8th day and 86% of being yeast . The viral pathogens leaded to infections in 6.8% of the patients(50% CMV,40% HBV,10% HCV) Febrile episodes were treated empirically with antipseudomonal beta lactam+ aminoglycoside or Ceftazidime,Imipenem or Cefoperazone + aminoglycoside or Vancomycin/Teicoplanine + aminoglycoside. Antibiotics were modified according to culture sensitivities.Infections were the only reason of death in 4/84(5%) of the patients.Out of 84 patients 53 (63%) are alive and well 27 patients (32%)died of relapse, GvHD. In our patients the existence of Gram-negative infections leaded us to modify our gut decontamination protocols. Addition of Quinolone may give some benefit. No case was lost due to Gram-positive infections 2 cases succumbed to death because of Aspergillus septicemia .
In conclusion, with the supportive care and the introduction of new more effective and less toxic antimicrobial regimens, use of immunobiological agents, Laminar Air Flow rooms reduce infection and transplant associated mortality and thereby improving the acceptability of SCT as a treatment option for an ever widening array of malignant diseases.
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Atypical presentation of homozygous RAG1 G1323A mutation, treated successfully with MUD SCT J.G. Noordzij, E.A.M. Sanders, M. van der Burg, A. van Royen, N.M. Wulffraat, J.J.M. van Dongen (Utrecht, Rotterdam, NL) At age of 20 months, a girl was admitted with chronic diarrhea and wasting. Earlier she suffered from a severe and prolonged infection with Varicella. Her blood cell count was 7.8x 10^9/L with a marked shift to t he left in the myeloid lineage and 22% lymphocytes. Bone marrow aspirate excluded a leukemia. There was an absence of B cells in the peripheral blood. Her IgA was 0.02 g/L, IgG nor detectable and IgM 0.01g/L. Her T cell numbers and function were normal at onset (total 1800 per microliter; CD3: 64%; CD4: 40%; CD8: 23% CD57: <1%), but gradually decreased over 2 years time (CD3 500/microliter). She was put on gammaglobulin suppletion and cotrimoxazole prophylaxis. Due to the progressive lymphopenia, the known causes of SCID were analysed. To our surprise, mutation analysis of the RAG1 gene showed a homozygous RAG1 G1323A mutation, with an amino acid substitution in the core domain (R404Q). An identical mutation was earlier found in a Dutch family (two sisters with SCID; mutated RAG1 allele with polymorphism). Due to the progression of her disease, she was treated with a SCT using a 9/12 matched MUD (mismatched at DRB1, DQB1 and DPB1). She was conditioned using busulphan, cyclophosphamide and ATG. She received a T cell depleted graft containing a CD34+ cell dose of 4.7 x 10^6/L and 0.03 x 10^5 /L CD3+ cells. Her granulocyten were >500 after 22 days and her platelets >20.000 after 26 days. Donor chimerism was 100%. Her clinical recovery was completely uneventfull. There were no signs of GVHD. Ciclosporin prophylaxis was tapered and stopped after 3 months. B cells returned within 2 months. Gammaglobulin suppletion was stopped after 9 months. Her T cell number is slowly increasing. * months after SCT she has 400 CD3/microlit, with near normal proliferative responses in vitro. This case illustrates that RAG1 mutations may be associated with a variety of conditions, ranging from SCID, Omen's syndrome to atypical agammaglobulinaemia.
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TNFA and GIFN are increased in bone marrow cells from Fanconi's anemia patients and TNFA suppresses erythropoiesis in vitro C. Dufour, A. Corcione, J. Svahn, V. Poggi, A. Bekassy, R. Scimè, R. Haupt, A. Pistorio, V. Pistoia (Genoa, Naples, Palermo, I, Lund, S) The current information on bone marrow failure in FA (Fanconi Anemia)show that myelosuppressive cytokines IFNg and TNFa, have a key role in causing the death of hemopoietic cells via increased apoptosis. We assessed the intracytoplasmic expression of TNFa, IFNg and MIP1a by flow cytometric analysis of MNCs derived from the bone marrow of FA patients and normal controls. We also studied surface expression of FasL and the effect of TNFa neutralization on the growth of erythroid progenitors from patients and controls. Bone marrow MNCs from 7 FA patients, (1 male, 6 females, mean age 9 years, range 2 -16 years, 4 of complementation group A, 1 of group C, 2 n.d., all infection free and untransfused, 6 with marrow failure) and from 8 marrow voluntary donors were cultured for 5hrs with PMA and ionomycin and tested by flow cytometry for intracytoplasmic accumulation of TNFa, IFNg, and MIP1a and surface expression of FASL. Erythroid progenitors were grown in methylcellulose with and without anti TNFa molecule (etanercept). Cytokine expression: In the patients TNFa content in all tested marrow MNC subsets (CD3+,CD3-ve and myeloid cells), both if expressed as percentage of positive cells and as MRFI, resulted highly significantly increased (P=0.006) as compared to the controls in whom no cytokine was detectable. The expression of gIFN in the patients was higher than in the controls in all tested marrow cellular subsets. Statistical significance was achieved in 3/6 of the assessed combinations (gIFN+/CD3+ cells evaluated as percentage-P=0.006-and as MRFI-P=0.006-; gIFN+/ myeloid cells evaluated as percentage-P=0.006-). The patients and the controls did neither express intracytoplasmic MIP1a nor surface FAS L in CD3+, in CD3-ve and in myeloid stimulated marrow cells.This occurred both when cytokine expression was evaluated as percentage of positive cells and as MRFI. Erythroid colony growth. In the control group when anti TNFa was added to the culture no differences were seen in the size and in the number of colonies. In the patients, the addition of anti TNFa provoked a significant in increase of both the size and the number of the CFU-e (P=0.043) and BFU-e (P=0.043) as compared to values with no anti TNFa. Conclusion: These data indicate that marrow MNCs of FA patients overexpress TNFa and gIFN, but not FAS-L or MIP1a. In addition, marrow culture studies suggest that FA patients have some degree of TNFa-mediated suppression of the erythropoiesis.
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Allogeneic bone marrow transplantation is a promising treatment option for hemophagocytic lymphohistiocytosis: the Hamburg experience N. Fehse, M. Dürken, U. Kordes, J. Schrum, F. G. von Finckenstein, N. Kröger, H. Kabisch, R. Erttmann, H.-H. Hellwege, T. Zabelina, B. Fehse, G.E. Janka, A.R. Zander (Hamburg, D; Ferrara, I) Hemophagocytic lymphohistiocytosis (HLH) represents a spectrum of rare, eventually fatal diseases usually of early infancy. Both familial (autosomal recessive) and spontaneous forms have been described. HLH is characterized by the overwhelming activation of T lymphocytes and macrophages leading to uncontrolled release of cytokines and prostaglandins with histiocytic and lymphocytic infiltration in multiple organs. Main features of HLH include persistent fever, hepatosplenomegaly accompanied by pancytopenia, hypertriglyceridemia, hypofibrinogenemia with histologic evidence of hemophagocytosis. Involvement of the central nervous system may vary from irritability to severe seizures and encephalopathy. Allogeneic BMT is the only current curative option for HLH, but high mortality has been observed especially for matched unrelated transplants. We report here on 17 consecutive patients treated with allo-BMT in Hamburg between 08/1992 and 06/2002. Conditioning therapy consisted of Busulfan (14-20 mg/kg), Cyclophosphamide (120 mg/kg), VP-16 (30-60 mg/kg) and Fresenius ATG (1-4 x 30 mg/kg). GvHD prophylaxis was carried out with Cyclosporin A and Methotrexate. Of these patients, 10 received BM from unrelated donors (7 identical, 1 A-MM, 1 B-MM, 1 DRB1/DPB1-MM) and 1 patient was transplanted with cord blood (1 A-MM, 2 B-MM). 5 patients were transplanted with BM from matched siblings, the remaining patient received haploidentical CD34+-enriched PBSC from his father. 15 patients engrafted well (one after second BMT at day 37) and are alive without HLH (follow up: 16-123 mo). Both, the patient with the CB graft and the one with an haplo-PBSCT experienced graft failure and subsequently died. Of the 15 patients who engrafted, 8 developed acute (7 grade I-II, 1 grade III) and two signs of chronic GvHD. One patient has severe retardation with blindness. We conclude that allogeneic bone marrow transplantation from either related or matched unrelated donors is a promising treatment option for HLH.
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Risk factors in pediatric stem cell transplantation for leukemia A. Gustafsson Jernberg, M. Remberger, O. Ringdén, J. Winiarski (Stockholm, S) Objectives: To investigate which factors impact on survival, relapse, RFS, transplant related mortality (TRM) and GVHD in children who undergo allogeneic stem cell transplantation due to leukaemia. Methods: All 181 children with leukaemia transplanted 1980-2000 at our unit were included in the study. Risk factors identified in univariate analysis were brought into a multivariable analysis. The median time of follow up was 7,5 years. Results: The 5 -year probabilities of acute GVHD grade II-IV, TRM and relapse-free survival (RFS) were 21%, 18% and 49%, respectively. Survival was similar in recipients of related (55%) and unrelated grafts (48%) (p=0.61). Stage of disease (=>CR 2) was an independent predictor for relapse, RFS and survival. The year of transplantation was another independent predictor of relapse, the probability of which increased significantly after 1992. Chronic GVHD, however, independently decreased the risk of relapse (RR 0.39) and death (RR 0.42). A donor positive for 3-4 herpes viruses increased the risk of acute GVHD, TRM and death, while a female to male transplant increased the risk of TRM, particularly if combined with a mismatch. HLA-matching independently improved, survival, RFS and TRM. Conclusion: Unrelated donor was not identified as a risk factor for any of the five endpoints. In children with leukaemia other more specific donor characteristics such as HLA-matching, herpes virus serology, immunization and sex emerge as more important for outcome.
Additional abstracts to this topic
Peripheral blood stem cell transplantation for Egyptian children with severe acquired aplastic anemia Y. Al-Tonbary, H. Mahmoud, O. Salama, M. Abou El-Kheir, A. Mansour, M. Sarhan (Mansoura, Cairo, EGY) Objective: Severe aplastic anemia (SAA) is a life threatening bone marrow failure disorder characterized by pancytopenia and a hypocellular marrow. The aim of this work is to evaluate the efficacy, cost benefit, and morbidity of allogeneic peripheral blood stem cell transplantation (PBSCT) in egyptian children with severe acquired aplastic anemia. Methods: PBSCT has been performed in 18 patients with SAA (11 males and 7 females) with age range 3-15 years (median= 10) and body weight ranged from 14 to 68 kg (median= 30.3). SAA was defined according to the International Aplastic Anemia Study Group as: (1) a granulocyte count of <0.5X10 9/L; (2) a platelet count of <20X10 9 /L; and (3) a hemoglobin level of <80g/L or a hematocrit level of <20% or a reticulocyte count of <50X10 9/L. Congenital forms of aplastic anemia were not considered. Conditioning regimen includes Antithymocyte Globulin (ATG): 10mg/kg/day I.V.I for 3 days followed by cyclophosphamide (CY): 50mg/kg/day I.V.I for 2 days. Results: The overall survival and the disease free survival were 66.6% as death has occured in 6 patients post-transplantation. Acute and chronic graft-versus-host disease were encountered in 50% and 0% of cases respectively. The median time for WBCs engraftment was 12 days and for platelet engraftment was 13.5 days. The median dose of CD34+cells was 6.39X10 6/kg of recipient's body weight. Conclusion: Allogeneic PBSCT offers high cure rate with acceptable toxicity for patients with SAA. The mortality rate is similar to other European and American Centers and the risk of death with immunosuppresive therapy is similar or even more than that of transplantation.
Long-term results of allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood
S. Santarone, P. Bavaro, G. Di Girolamo, P. Olioso, G. Papalinetti, P. Di Carlo, M.T. Massaro, P. Di Bartolomeo (Pescara, I) CML is a rare malignancy in childhood. In this retrospective study we update the outcome and long-term follow-up of 10 patients (7 males and 3 females) who were transplanted in our Institution between 01/1983 and 09/2001 from HLA-identical family donor. All patients showed typical clinico-biological features of adult type CML. The presence of the Philadelphia chromosome was found in 9 of them. The median age at BMT was 14 years (6-18). The median interval between diagnosis and BMT was 10 mo (2-16). At time of BMT 9 patients were in 1st and 1 in 2nd chronic phase. Seven patients were conditioned with fractionated TBI and Cy and 3 with the BuCy regimen. GvHD prophylaxis consisted of CSA alone in 5 patients and CSA + short course MTX in 5 patients. The median dose of nucleated marrow cells was 3.4x10E8/Kg (2.8-6.8). Engraftment of donor cells was confirmed in all patients. The median time to reach 0.5x10E9/L PMNs and 25x10E9/L PLTs was 26 days (17-60) and 21 days (10-60) respectively. Five patients had no evidence of aGvHD, 4 grade I and 1 grade II. Chronic GvHD was evident in 4 patients (limited in 2 and extensive in other 2). One patient died 27 mo after BMT because of cGvHD and bacterial encephalitis. Two patients showed hematologic and cytogenetic relapse at 36 and 32 mo post-BMT. They were retransplanted from the same donor at 30 days and 62 mo respectively after the first BMT. At time of this report 9 patients are living and doing well without any evidence of the original disease after a median follow-up of 16.02 years (1.01-19.09). The estimated 10-years DFS and EFS probabilities are 89% and 67% respectively. All patients were examined on October 2002 for evaluation of late effects. At that time 7 patients have developed posterior capsular cataract, 1 patient HCV related chronic active hepatitis successfully treated with alpha interpheron, 3 hypothiroidism, 1 familial diabetes. The 2 female evaluable patients show amenorrea. Gonadal function was evaluated in 3 male recipients. Two of them are affected by azoospermia and one recovered normal testicular function. His partner became pregnant 14 years after BMT and delivered a normal baby. No patient show evidence of cardiac or pulmonary late effects. These data confirm that allogeneic BMT offers a curative treatment option for the majority of children affected by adult type CML. Patients with a matched sibling donor should undergo BMT as early as possible following diagnosis.
Allogeneic stem cell transplantation in children -a single center experience S. Sufliarska, I. Bodova, J. Horakova, J. Lukac (Bratislava, SK) Since 1995 allogeneic stem cell transplantations (SCT) in children are performed at the BMT Unit of the Pediatric University Hospital in Bratislava. We analyzed the results of 37 allogeneic SCT from HLA-matched siblings and matched unrelated donors (MUD) in 36 patients, done between November 1995 and November 2002. Patients aged 3 to 17 years underwent allogeneic SCT for acute leukemia (15), NHL (2), Ewing sarcoma (1), acquired aplastic anemia (10), WiskottAldrich syndrome (1), Diamond-Blackfan anemia (2). All, but one patient, were transplanted for the first time. Donors aged 6 month do 23 years, were in 30 cases HLA-identical siblings and one was a syngeneic donor. 5 patients were transplanted from a MUD. The preferred source of stem cells was peripheral blood in 27 cases (3 MUD), less often, in 7 cases (2 MUD), it was bone marrow and 3 times umbilical blood was used. The patients received a median of 3,5 x 106/kg per body weight CD34+ cells (range 1,6-12,4 x 106/kg) and 4,9 x 108/kg CD3+ cells (range 1,5-11,5 x 108/kg). All patients engrafted, reaching an ANC>0,5 x 109/l after a median of 16 days (range 10-28 days), were as S241 patients with malignant diseases engrafted after a median of 13 days and with non-malignant diseases, predominantly aplastic anemias, after 16 days. Acute GVHD (aGVHD) grade II to IV developed in 13 out of 37 (35%) transplants, two of these patients had grade IV aGVHD. Chronic GVHD (cGVHD) occurred in 13 of 34 (38%) evaluated patients, were as 8 out of 34 (22,8%) patients suffered extensive. After a median follow-up of 634 days (range 55-2538 days) 24 patients (66,6%) are alive with sustained engraftment and durable remission of their underlying disease. 12 of the 36 transplanted patients died, were as 8 of them due to relaps of leukemia, two patients died of grade IV aGVHD (5,5%) and two due to an infectious complication. Based upon our experience the survival of pediatric patients after HLA-matched allogeneic related and unrelated SCT even in a cohort where the predominantly used source of stem cells are peripheral blood stem cells is comparable with bone marrow setting, with rapid engraftment and no greater incidence of acute or chronic GVHD.
Serum nitric oxide level in children undergoing allogeneic BMT M. Cetin, D. Uckan, H. Okur, Y. Tezcan, M. Tuncer (Ankara, TR) Due to the close association of nitric oxide (NO) levels with biologic functions, the investigation of NO levels in BMT patients may have a role in risk determination.Serum NO levels were serially measured at days -9,+7,+21,+28 and +3 mo and 6 mo in 26 children who underwent allogeneic BMT for hematological, immunological and metabolic diseases. Nine patients suffered from transplant complications including grade III/IV GvHD, severe infection, VOD and drug toxicity (Group I). The transplant course was uneventful in the remaining 17 patients (Group II). No statistically significant difference in serum NO levels was noted after BMT when compared to baseline levels in both groups. However, the pre-transplant and day +28 serum NO levels were significantly higher in group I (2.8±1.0, 3.3±1.8 respectively) when compared to group II values (1.8 ±1.3, 2.0±1.3 respectively) (p<0.05). This preliminary study may suggest a role for pre-BMT serum NO levels in risk assessment in BMT patients.
Secondary thrombocytopenia after platelet engraftment not due to relapse, predicts a dismal outcome V. Bordon, C. Dhooge, E. Vandecruys, J. Verlooy, G. Laureys, Y. Benoit (Ghent, B) Secondary thrombocytopenia after hematopoietic stem cell transplantation, with or without neutropenia may develop for other reasons than recurrence of the primary disease. We made a retrospective analysis of this complication in our unit. Material and methods: Between January 1993 and august 2001, 64 consecutive paediatric allogeneic transplants were retrospectively studied. Secondary thrombocytopenia was defined as platelets <20000/mm³ for 7 consecutive days after initially reaching >50000/mm³ in the absence of transfusions, for at least 1 week. Neutropenia was defined as neutrofils <500/mm³, for at least 2 days. Results: 64 paediatric allogeneic transplants were performed in our unit. The median age at transplantation was 6.9 years (3 months to 15 years).Type of transplants: identical sibling donor transplants(n=28), matched unrelated donor (n=30), familiar other than sibling (n=4) and haploidentical transplants (n=2) Secondary thrombocytopenia developed in 10 patients (15.6%). Median time of onset after transplant was day +98 (range 37-344). Resolution of this complication was only seen in 3 cases, at days +78, +201 and +500. In 7/10 cases the thrombocytopenia never resolved and patients finally died. Transplant Related Mortality was 70% in this group compared to 31% in the patients without secondary thrombocytopenia (P= 0.032). Concomitant neutropenia was seen in 4 cases The aetiology was multifactorial: thrombotic thrombocytopenic purpura in 2 patients, severe acute hepatic GvHD in 4, systemic fungal infections in 2, 1 patient with CMV disease and 1 patient with EBV lymphoproliferative disease. All 10 patients suffered or have antecedent of acute GvHD grade II-IV. In a univariate analysis of risk factors for secondary thrombocytopenia development, we found that the antecedent of acute GvHD grade II-IV was an important risk factor (P <0.001) while donor other than sibling (P 0.48) and CMV status (P 0.49 for developing of secondary thrombocytopenia. Graft rejection and/or autologous reconstitution was not seen in patient with this complication. Conclusions: Secondary thrombocytopenia is a severe and multifactorial complication with a very poor outcome. Adequate treatment of the underlying disease, improvement in the prevention and treatment of the acute GvHD and aggressive supportive care should improve the survival in these patients.
Learning deficits after cyclosporine A neurotoxicity V. Bordon, C. DHooge, S. Bravo, E. Vandecruys, J. Verlooy, G. Laureys, Y. Benoit (Ghent, B) Introduction: Up to 5% of the patients who receive Cyclosporine A (CsA), may experience severe CsA neurotoxicity. We describe a girl with an acute posterior encephalopathy a nd very good neurological recovery but with persistent learning deficits after CsA neurotoxicity. Case Report: A 9 year-old girl with ALL in second CR received a PBSC transplant from her HLA-identical sibling, following conditioning with TBI, Ara-C and melphalan (TAM 12). GvH prophylaxis consisted in a short course of MTX and CsA with daily monitoring (plasma levels: 100-200 ng/mL.) On day + 42 she developed acute GvHD grade 3 and Methylprednisolone 2 mg/kg I.V. was started and we added Budesonide 9 mg/day P.O. for intestinal GvHD-resistant to the methylprednisolone. She responded well and after 23 days of treatment with methylprednisolone, steroids were tapered. On day +75 the girl developed a leukoencephalopathy with cortical blindness and seizures, without severe hypertension. Brain MRI revealed hyperintensity signals in the left frontal and temporo-parietooccipital zones, with lesions in cerebral cortex as well as in subcortical white matter. At the time of deterioration, CsA levels were 660 ng/ml, 3 hours after intake of CsA. After withdrawal of CsA, the girl had a rapid neurological recuperation but with persistent learning deficits 7 months after the insult. Brain MRI shows calcifications in the posterior associative area. Discussion: The clinical presentation of the posterior encephalopathy due to CsA is a well know entity and is characterised by headaches, alteration in the mental status, cortical blindness, seizures and coma. Little is known however about the cognitive outcome in paediatric patients who experienced a severe acute encephalopathy. Persistent learning difficulties and calcifications in the posterior area on MRI are found in our case, 10 months after transplant. Longer follow-up is needed to confirm if this clinical picture is reversible or not. We conclude that a close and long-term neurological and cognitive perfomance follow-up are needed after CsA neurotoxicity in order to evaluate the incidence and impact of this complication in children.
Quality of life: the wish to quantify the immeasurable?
A. Di Gallo, R. Felder-Puig, M. Guenter, I. Stohrer, R. Topf, D. Buergin (Basel, CH; Vienna, A; Tuebingen, D) Objectives: With the enormous progress of medicine in the last decades, terms like "coping" or "quality of life (QoL)" increasingly acquired a fundamental meaning. Research was no longer merely interested in whether someone survived an illness, but also in how and at what price. The need for conceptualisation and quantification of health-related QoL arose. QoL today represents an important aspect in the evaluation of the course and outcome of medical interventions. The paper discusses current concepts of QoL, their strengths and limitations in the assessment of children undergoing SCT. Methods: Scientific literature on QoL preferring "objective" methods is presented and contrasted to the clinical practice, where a qualitative approach is mainly used. Strengths and
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shortcomings of both are discussed. Results: Number and range of instruments measuring QoL have considerably increased in the last years. However, there is still a lack of agreement regarding concepts and assessment of QoL. Definitions include multi-dimensional concepts assessing physical, psychological and social functioning as well as alternative concepts defining QoL as the discrepancy between actual and ideal capacities. Discrimination of QoL from psychosocial and physical condition or pathology has not been clearly defined, and the source of information (patient vs. proxy report) plays a significant role in the assessment of QoL. Semiquantitative methods assessing the psychic state of the patient have been developed especially for children and give us insight into the emotional processes which help the children to adapt to the situation. Conclusion: Agreement regarding standards and the refinement of the available measuring tools should be a priority of future research. In addition, standardized questionnaires should be combined with qualitative measures, since patients' experiences associated with challenges such as haematological stem cell transplantation are too complex to be reduced exclusively to comparisons with healthy people using standardized psychometric instruments. Life is a quality and always contains a personal "excess" that cannot be measured quantitatively. Thus, a person's individual way of living and being, with all its ambiguity, rational and irrational aspects, is, in the end, understandable only through narrative, that is through the hearing of the personal life story.
Electroencephalogram abnormality and seizure after highdose busulfan in pediatric stem cell transplantation M. Ertem, T. Ileri, G. Deda, F. Azik, O. Unal (Ankara, TR) High-dose busulfan (BU) is frequently included as a part of the myeloablative regimen prior to stem cell transplantation (SCT) to avoid total body irradiation especially for children. Although in young children, the incidence of BU related toxicities are less than adults, higher rates of graft rejection or relapse occur. Recent studies have demonstrated that the pharmacokinetics of BU are age-dependent and this has lead to the development of protocols with higher doses of BU based on body surface area (BSA). Since the introduction of higher doses of BU in conditioning regimens several cases of seizures have been reported. The use of preventive anticonvulsants has been described but seizures still occur after prophylaxis especially on the last day of BU therapy. We conducted a study to evaluate the acute neurotoxicities, the electroencephalogram (EEG), visual and brain stem auditory evoked potential (VEP and BAEP) abnormalities in children after receiving higher doses of BU for SCT. All the consecutive pediatric SCT patients who received high-dose BU between April 1998 to November 2002 were included to the study. None of the patients received anticonvulsant prophylaxis except one with sickle cell anemia and CNS infarct. In this prospective observational study, we recorded EEG, VEP and BAEP before and on the last day of BU therapy. Of the total of 20 patients, 13 were males and 7 were females with a median age of 9.3 years (1.9 to 14.8 yrs). Ten patients had leukemia and 10 patients had hemoglobinopathy (thalassemia major:9, sickle cell anemia:1). The median actual dosage of BU calculated from BSA and body weight were 480 mg/m2 and 17.1 mg/kg (range 14.2 to 22.8 mg/kg) respectively. EEGs before BU administration were normal in all patients, on the last day of BU therapy however EEGs were abnormal in 7 patients (35%). None of the patients had a seizure. BAEP and VEP studies were all normal before BU therapy, but on the last day of therapy abnormal VEP results were obtained in one patients (5%). The preliminary results of this ongoing study indicate that there is no increased risk of acute neurotoxicity despite higher dose of BU in children even when anticonvulsive prophylaxis is not used. We believe the recommendation for widespread use of anticonvulsants during BU therapy should be reconsidered in the light of recent studies which point out the potential deleterious effects of diphenylhydantoin and phenobarbital on the BU activity.
Allogeneic peripheral blood stem cell harvest from pediatric sibling donors is effective and safe for transplantation T.S. Shamsi, M. Irfan, T. Farzana, S. Ansari, N. Shakoor, M. Baig (Karachi, PAK) Objective: To study the efficacy, safety and practicality of harvesting peripheral blood stem cells from HLA identical paediatric donor population of patients suffering from haematological disorders. Patients and Methods: Between September 1999 to October 2002, forty-two PBSC transplants were carried out in our centre for various haematological disorders. Out of forty-two donors, twenty-nine paediatric donors were harvested for haemopoietic stem cells using peripheral blood as its source using intermittent blood flow cell separator (MCS+, Haemonetics USA). They were HLA identical siblings and were primed with 10 mcg/kg of G-CSF for 4 -5 days. On 5th day the PBSC were collected and one and a half to two times the volume of each donor's blood was processed to obtain 5 × 108 mononuclear cells (MNC) per kilogram body weight of the recipient. If the MNC count was insufficient, then a second harvest taken on 6th day. Antecubital vein was used for venous access in all the donors except one. Blood flow rate was set between 20 -40 ml/minute. The cell separator was primed with 220 ml compatible blood to fill the dead space and then returned it to the paediatric donor during the return cycle. It was done to avoid more than 13% extra corporeal volume from the donor at any given time. Donors were monitored haemodynamically during the procedure. Results: Donors' median age was 7.9 years (3.16 SD). There were 20 male and nine female in the population. All were HLA identical with their recipients. Their mean height was 4.9 feet and mean weight was 27 kg. All of them were healthy on clinical assessment. Only one donor required femoral catheter (he was 3 and a half years old) while in all others antecubital vein was sufficient for blood flow. Body ache and low-grade fever were the main symptoms during G-CSF therapy. Mild thrombocytopenia was noted in all donors the day after PBSC collection. There was none other complications during one month follow up of the donors. Conclusion: This study has confirmed the feasibility and safety of mobilization and collection of PBSC from paediatric donors. Larger studies are warranted to see the long-term effects of PBSC mobilization and collection in paediatric donors.
Disseminated bacille Calmette-Guerin infection in infants
with X-linked severe combined immunodeficiency P. Sedlacek, P. Keslova, L. Sramkova, J. Bartunkova, O. Hrusak, R. Kodet, L. Krskova, R. Vajtrova, O. Nyc, M. Mullerova, J. Stary (Prague, CZ) Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccination is compulsory in all Czech infants, leading to population-wide coverage. Disseminated mycobacterial infection following BCG vaccination occurs mostly in immunocompromised patients. T cells and macrophages play an important role in protective immunity against tuberculosis. Over period of 2000 and 2001, four infants were newly diagnosed in Czech Republic with X -linked severe combined immunodeficiency syndrome (SCID). All were vaccinated by BCG vaccine in first days after delivery. Diagnosis of disseminated BCG infection was confirmed by examination of pus from site of vaccination and/or other skin lesions showing presence of acid-fast bacilli (AFB) in samples stained by ZiehlNielsen. Cultivation of pus was used to determine Mycobacterium bovis etiology. Histopathological specimens from skin and other organ biopsies were evaluated by a pathologist for demonstration of AFB. PCR assay was performed using blood and fluid from respiratory tract obtained from bronchoalveolar lavage. All four infants developed disseminated BCG infection despite proper anti-tuberculotic prophylaxis, in three following allogeneic hematopoietic stem cell transplantation (HSCT), in one during post-transfusion graft versus host disease. BCG etiology was confirmed in all patients. Children suffered mainly from fever, anemia, c utaneous lesions, osteitis and osteoporosis with pathological fractures and hepatosplenomegaly with hypersplenism. In two survivors chronic skin BCG persists months after successful HSCT despite reconstitution of T cell mediated immunity. Intensive and combined anti-tuberculotic treatment is provided in all patients. However it is not sufficient to prevent reactivations of BCG soon after HSCT. We hypothesized that not only specific T cell immunity but also engraftment and functional competence of donor-derived macrophages is crucial to treat BCG-itis. Therefore BCG infection even after HSCT remains severe and life-threatening complication and has to be considered in severely immunocompromised patients vaccinated previously with BCG vaccine. Work was partially supported from grants MSMT CR 111300001.
Efficiency of alemtuzmab in HSCT transplantation in children with high risk of rejection K. Drabko, J. R. Kowalczyk, B. Wojcik, M. Choma, A. ZauchaPrazmo, D. Turkiewicz, J. Toporski, E. Gorczynska, A. Chybicka (Lublin, Wroclaw, PL) In 2002, in two pediatric transplantation centers Wroclaw and Lublin (Poland) Altemzumab were administered in conditioning regiments before HSCT transplantation in 9 children (aged 1,8 -18). The indication for using Campath 1H as an immunoablative agent were high risk of rejection due to donor mismatch (3 patients) and previous transplants (6 patients). Patients were diagnosed as having ALL (2 pts), AML (1 pts), CML (2 pts), JMML (2 pts), non-malignant disease (2 pts). Conditioning regiment was based on Busulfan/Treosulfan in 5 children, Melphalan in 2 children, non-myeloablative regimen was introduced in 2 children. Altemzumab was given in daily dose of 10/mg/m2 (7 pts) and 15 mg/mh/m2 (2 pts) usually during four consecutive days. GvHD prophylaxis was CsA alone (4 pts), CsA + short course of MTX (2 pts), T depletion in vitro (CD 34 positive selection) in 3 patients. Engraftment was achieved in 8 of 9 patients. Four children are still alive in CR (median observation time on November 27th is 100 days). Five patients died, 4 of them died due to severe infections. We conclude, that Altemzumab is an effective immunoablative agent in transplants with high risk of rejection. However, the risk of severe infection in heavily pretreated patients is high.
PBSC collection for triple transplants in low weight children
A. Noguera, I. Alcorta, J. Estella, S. Rives, T. Toll, E. Tuset, A. Alvarez (Esplugues, E) Background: Repetitive megatherapy cycles are being increasedly used to treat solid tumors in children. High doses of PBSC (CD34+ > 5 x 10e6/kg) are used to support chemotherapy cycles and to avoid delays betwen courses. We report our experience in collecting PBSC for triple transplants in low weight (< 15 kg) children. Patients and Methods: Three children with newly diagnosed medulloblastoma and one with medulloblastoma relapsing after 1 year of initial therapy were planned to be treated with 3 sequential courses of high-dose chemotherapy with PBSC support. A 10 Fr apheresis catheter was placed into external yugular vein and chemotherapy consisting in Cisplatin 3.5 mg/kg (day 0), vincristine 0.05 mg/kg (days 0,7 and 14), cyclophosphamide 60 mg/kg (days 1 and 2) and etoposide 2.5 mg/kg (days 0,1 and 2) was administered. G-CSF 10 mcg/kg/day was started on day 5, and CD34 counts were performed from day 12 on. Harvests were initiated when CD34+ cell count exceeded 50 x 10e6/L and MNC count was greater than 5 x 10e9/L. Large volume leukapheresis processing 6 blood volumes were performed with a Cobe Spectra AutoPBSC procedure. The product obtained was split in 3 aliquots and cryopreserved in 5% DMSO at -80 °C in a mechanichal freezer. Results: The patients' sex, age, weight, preapheresis WBC, MNC and CD34 counts and CD34 content of the product obtained are shown in the table. Only one procedure was required to obtain the required amount of CD34+ cells. Two patients have already completed the triple transplant procedure with carboplatin 17 mg/kg (day 0 and 1) and thiotepa 12 mg/kg (days 0 and 1) with good hematological recovery and without delays between cycles. Conclusions: Adequate PBSC numbers for multiple transplants can be obtained in low weight children combining collection early in the course of the disease, a potent mobilizing regime with chemotherapy and G-CSF, and large volume leukapheresis
Autologous peripheral blood progenitor cell collection in pediatric patients S. Roncon, I. Barbosa, A. Avila, A. Campos, C. Vaz, F. Campilho, P. Pimentel, A. Carvalhais (Porto, P) Autologous peripheral blood progenitor cell (PBPC) transplantation can improve the prognosis of children with advanced solid tumours and hematologic malignancies. We report our experience with PBPC mobilisation and collection in 41 pediatric patients (Group I: n=17 age <10 years and Group II: n=24 age 10-16 years) referred to our center between March 1996 and October 2002. In both groups of patients, PBPC were mobilised with G-CSF (10µg/kg/day) alone or with chemotherapy (in the first 4 patients). Leukapheresis was performed using a continuous flow blood cell separator (Cobe Spectra) through a central venous catheter with double lumen. In Group I the majority of patients had solid tumours (10/14), the median age was 5 (range 2-8) years old, the body weight (BW) was 20kg (12-40Kg) and the total blood volume (TBV) 1651ml (863-2791ml). Extracorporeal line was primed in 14 patients with a mixture of leucocyte depleted RBC unit and normal saline, adjusted to the patient haematocrit. During collection the average blood flow rate was 40 (20-80) ml/min, the total blood volume processed/apheresis was 5.4l (2.4-11.2l ) and all the procedures were finished within 2hrs and 30 mins. The diagnosis of patients in Group II were predominantly hematologic malignancies (19/24), the median age was 13 years old, BW was 49kg (29-70Kg) and TBV 3018ml (1753-4700ml). The leukapheresis was carried out with higher flow rate 74 (30-106) ml/min, total blood recirculated 10.2l (4-17l) was also increased in comparison with Group I and the collection took up to 4 hrs. For both groups of patients the CD34+cell/kg target (>2.0x106 CD34+cell/kg) was achieved (95% for Group I and 88% for Group II) with a median of 2 collections (1-4 for Group I and 1-6 for Group II). Adverse reactions were mild (31% and 33% in Groups I and II, respectively) and mainly related to hypocalcemia. Our results show that G-CSF mobilisation and PBPC collection were feasible and safe for the harvesting of the graft for autologous transplantation in children, even in those with low-weight.
High-dose chemotherapy in children and adolescents with poor-prognosis Hodgkin´s disease
E. Kabickova, D. Sumerauer, P. Kobylka, E. Cumlivska, A. Vicha, J. Valkova, R. Kodet, J. Koutecky (Prague, CZ) Purpose: This retrospective analysis was undertaken to determine clinical prognostic factors and outcome of patients with Hodgkin`s disease (HD), who were treated with a salvage regimen of high-dose chemotherapy and autologous stem-cell transplantation (ASCT). Patients and methods: Twenty-nine patients with poor-prognosis HD, of whom 16 were boys, underwent megatherapy between January 1992 and December 2001. The reasons for consolidation high-dose chemotherapy were: poor initial response to first-line chemotherapy (8x) or relapse (21x). The median age at ASCT was 16,3 years (range 10.8 to 22.5). Thirty-five percent of patients had stage II disease, 48% had stage III disease, and 17% had stage IV disease. The conditioning contained cyclophosphamide, etoposide and busulfan or carmustine. Bone marrow was used as the source of hematopoietic stem cells in 5 patients, peripheral blood in 19, and both in five. Results: After a median follow-up of 84 months the overall survival and event-free survival is 72%. Eight patients died by disease progression, 3 secondary to infectious complications. Median time to relapse after transplantation was 7,5 months. The pretransplantation disease status after salvage therapy was the only significant prognostic factor for survival. Conclusion: High-dose chemotherapy followed with autologous hematopoietic rescue represents the best therapeutic option for children with poor-prognosis Hodgkin`s disease and is associated with acceptable toxicity. Superior results were seen in patients with chemosensitive disease and minimal tumor burden at the time of transplantation.
PBPC collection with AMICUS separator results in reduced risk of post-harvest thrombocytopenia and low platelet contamination of apheresis product J. Toporski, D. Turkiewicz, E. Gorczynska, K. Kalwak, A. Chybicka (Wroclaw, PL) High platelet collection efficiency typical for commonly used blood cell separators results in high platelet (PLT) content of the apheresis product and post-harvest thrombocytopenia in a donor. Thrombocytopenia is severe if 2 or more aphereses are required to obtain high number of hematopoietic progenitors. This side effect is of a great concern in pediatric donors. PLTs contaminating apheresis product interfere with graft processing such as immunoselection of cells. We present our experience with PBPC collection with the use of AMICUS cell separator (Baxter). Material: PBPCs were harvested from 8 patients with malignancies (AML 2, ALL 2, NBL 2, NHL 1, HD 1) with median age of 9 (3.5-21) years and 3 adult healthy donors. Median weight of apheresed children was 30 (17-64) kg. Children were mobilized with a combination of chemotherapy and G -CSF, healthy donors with G-CSF only. Methods: In donors and 4 patients two-lumen central venous catheter was inserted into femoral vein for blood withdrawal and return. Four patients had 2 single lumen catheters inserted into both femoral veins. Apheresis procedure was performed according to manufacturer instructions. Donors had 2 subsequent procedures. Patients underwent single apheresis. In all cases complete blood count was done before and after collection. Number of CD34+ cells was assessed with flow cytometry in peripheral blood before apheresis and in the apheresis product. PLT and white blood cell counts and percentage of mononuclear cells were measured in the product. Viability of cells was evaluated with trypan blue staining. Results: Median procedure time was 210 (150-330) min. Median volume of blood processed per kg of donor/patient weight was 178 (101-295) ml. Citrate toxicity occurred only in 1 adult female donor. Decrease of donors' PLT counts after 2 collections was 5%, 13% and 15% of the initial value. In patients median decrease of PLT count was 14% of initial value and ranged from 2 to 28%. The most profound decrease was observed in a child with 295ml/kg of processed blood. No blood product support was necessary. Median PLT count in the apheresis product was 535 (163-959) x10^9/L. Median number of collected MNCs was 1.34 (0.7-3.32)x10^10 with 0.85 (0.27-13.5)% of CD34+ cells.
Conclusions: MNCs separation with AMICUS is safe and feasible in children and donors. PLT depletion after aphersis is of no clinical relevance. Low PLT content in the product facilitates further graft processing.
Amphotericin B treatment and nephrotoxicity in immunocompromised children: a 7-year experience C. van der Feen, T. Wolfs, M. Bierings (Utrecht, NL) Invasive fungal disease remains one of the major causes of morbidity and mortality in immunocompromised patients. Many children with malignant diseases who develop fever during neutropenia, not responding to broad spectrum antibiotics, receive conventional amphotericin B (AmB) empirically. However, the side effects of AmB are severe and include nephrotoxicity. Recently the effect of switching to amphotericin B lipid complex (ABLC) or liposomal amphotericin (L Amph) has been advocated as a useful, although expensive, alternative to reduce nephrotoxic side effects. Although many studies have concentrated on nephrotoxic side effects in adults, very few data have been collected on paediatric patients. We studied all 23 patients with a history of AML or allogenic BMT who received AmB therapy, admitted to our hospital from 1995 to 2002. The mean duration of therapy was 13.4 days, and the mean cumulative dose was 11.8 mg/kg. The majority of the cases (n=15) received AmB treatment for persistent fever in neutropenia under broad spectrum antibiotics, while in 4 cases there was a proven invasive fungal infection. The remaining group (n=4) presented with persistent fever ánd candida in faeces or a suspected fungal lesion on computer tomography. 10/23 (43%) children developed nephrotoxicity, of whom 2 cases had moderate nephrotoxicity (>50% but <100% increase in baseline serum creatinine level) and 8 cases had severe nephrotoxicity (>100% increase). Because of the severe nephrotoxicity 7 patients switched to ABLC or L Amph. A decrease in serum creatinine to baseline level was seen in 3 cases (43%) after switching. Two cases (29%) showed a significant decline, but remained above the doubled baseline creatinine value and in two cases (29%) serum creatinine levels did not decrease. After discontinuation of treatment serum creatinine level returned to baseline values in each surviving patient. In this study we found a relatively high incidence of nephrotoxic side effects of AmB treated children as compared to previously reported results in adult groups. In 5 out of 7 cases switching to a lipid form of AmB improved nephrotoxic side effects.
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HLA expression and immunologic properties of differentiated and undifferentiated adult and fetal mesenchymal stem cells K. Le Blanc, C. Götherström, C. Tammik, O. Ringden (Stockholm, S) Aim: Previous work has demonstrated that undifferentiated adult MSC do not elicit alloreactive T cell proliferative responses in vitro due to suppressive mechanisms. We investigated the immunologic properties of adult and fetal liver derived MSC after differentiation to bone, cartilage and adipocytes. Methods and Results: Adherent mononuclear cells from adult bone marrow and fetal liver (gestational week 9-13) were ex vivo expanded and stained positive for SH2, SH3 and SH4. By flow cytometry, undifferentiated aMSC express intermediate levels of HLA class I but no class II although HLA class II was detected by western blot on whole cell lysates. Fetal MSC expressed lower levels of HLA class I but no class II on the cell surface nor contain any intracellularly. Addition of IFN-gamma for 48 hours
